Fusion protein of an exendin to modified transferrin

ABSTRACT

The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent applicationSer. No. 11/782,030, filed Jul. 24, 2007, now allowed, which isincorporated herein by reference, and which claims priority, under 35U.S.C. §119(e), to U.S. Provisional Application Ser. Nos. 60/832,582,60/857,474, and 60/874,965, filed on Jul. 24, 2006, Nov. 8, 2006, andDec. 15, 2006, respectively, the entire disclosures of which areincorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to fusion proteins comprising an exendin-4and a transferrin and uses thereof for the treatment of diseasesassociated with elevated glucose serum levels such as Type II diabetes,and to reduce body weight. The fusion protein of the invention can alsobe used to treat other diseases known to benefit from treatment withexendin-4 and other GLP-1 receptor agonists such as Type I diabetes,congestive heart failure, myocardial infarction, irritable bowelsyndrome, neurological diseases such as Alzheimer's disease andHuntington's disease, and non-alcoholic, non-fatty liver disease.

BACKGROUND OF THE INVENTION

Diabetes refers to a disease process derived from multiple causativefactors and characterized by elevated levels of plasma glucose orhyperglycemia in the fasting state or after administration of glucoseduring an oral glucose tolerance test. There are two generallyrecognized forms of diabetes. In Type diabetes, or insulin-dependentdiabetes mellitus (IDDM), patients produce little or no insulin, thehormone which regulates glucose utilization. In Type II diabetes, ornon-insulin dependent diabetes mellitus (NIDDM), patients often haveplasma insulin levels that are the same or even elevated compared tonondiabetic subjects. However, these patients have developed aresistance to the insulin stimulating effect on glucose and lipidmetabolism in the main insulin-sensitive tissues, which are muscle,liver and adipose tissues. The plasma insulin levels, while elevated,are insufficient to overcome the pronounced insulin resistance,resulting in hyperglycemia.

Persistent or uncontrolled hyperglycemia is associated with increasedand premature morbidity and mortality. Often abnormal glucosehomeostasis is associated both directly and indirectly with alterationsof the lipid, lipoprotein and apolipoprotein metabolism and othermetabolic and hemodynamic diseases. For example, patients with Type IIdiabetes mellitus are at especially increased risk of macrovascular andmicrovascular complications, including coronary heart disease, stroke,peripheral vascular disease, hypertension, nephropathy, and neuropathy.

Obesity and being overweight are generally defined by body mass index(BMI), which is correlated with total body fat and serves as a measureof the risk of certain diseases. BMI is calculated by weight inkilograms divided by height in meters squared (kg/m²). Overweight istypically defined as a BMI of 25-29.9 kg/m², and obesity is typicallydefined as a BMI of 30 kg/m² or higher. See, e.g., National Heart, Lung,and Blood Institute, Clinical Guidelines on the Identification,Evaluation, and Treatment of Overweight and Obesity in Adults, TheEvidence Report, Washington, D.C.: U.S. Department of Health and HumanServices, NIH publication no. 98-4083 (1998).

Overweight or obese individuals are at increased risk for ailments suchas hypertension, dyslipidemia, Type II (non-insulin dependent) diabetes,insulin resistance, glucose intolerance, hyperinsulinemia, coronaryheart disease, angina pectoris, congestive heart failure, stroke,gallstones, cholescystitis, cholelithiasis, gout, osteoarthritis,obstructive sleep apnea and respiratory problems, gall bladder disease,certain forms of cancer (e.g. endometrial, breast, prostate, and colon)and psychological disorders (such as depression, eating disorders,distorted body image and low self esteem). The negative healthconsequences of obesity make it the second leading cause of preventabledeath in the United States and impart a significant economic andpsychosocial effect on society. See, McGinnis M, Foege W H., “ActualCauses of Death in the United States,” JAMA 270:2207-12, 1993.

Obesity is now recognized as a chronic disease that requires treatmentto reduce its associated health risks. Although weight loss is animportant treatment outcome, one of the main goals of obesity managementis to improve cardiovascular and metabolic values to reduceobesity-related morbidity and mortality. It has been shown that 5-10%loss of body weight can substantially improve metabolic values, such asblood glucose, blood pressure, and lipid concentrations. Hence, it isbelieved that a 5-10% reduction in body weight may reduce morbidity andmortality. Currently available prescription drugs for managing obesitygenerally reduce weight by decreasing dietary fat absorption, as withorlistat, or by creating an energy deficit by reducing food intakeand/or increasing energy expenditure, as seen with sibutramine.

Current treatments for Type II diabetes include administration ofexogenous insulin, oral administration of drugs and dietary therapiesand exercise regimens. In 2005, exenatide (exendin-4; Byetta®) was FDAapproved as an adjunct therapy for Type II diabetics who are takingmetformin and/or a sulfonylurea but who have not achieved adequateglycemic control. Exenatide is exendin-4, a potent GLP-1 receptoragonist that is an endogenous product in the salivary glands of the Gilamonster. Like GLP-1, exendin-4 is an incretin. It is insulinotropic,inhibits food intake and gastric emptying, and is trophic to β-cells inrodents (Parks et al., Metabolism. 50: 583-589, 2001; Aziz and Anderson,J. Nutr. 132: 990-995, 2002; and Egan et al., J. Clin. Endocrinol.Metab. 87: 1282-1290, 2002). Further, due to the presence of glycine atposition 2 of its N-terminus, it is not a substrate for DPPIV, as isGLP-1. The downside to the use of exenatide is that it must be injectedtwice daily because its t_(1/2) is only 2-4 hours (Kolterman et al., J.Clin. Endocrinol. Metab. 88: 3082-3089, 2003 and Fineman et al.,Diabetes Care. 26: 2370-2377, 2003).

Accordingly, a need remains for a longer-fasting, degradation resistantGLP-1 receptor agonist molecule that can be used as a therapeutic toprovide glycemic control and to reduce body weight. Development of along acting incretin mimetic offers the ability to enhance glycemiccontrol through continuous enhancement of glucose-dependent insulinsecretion, with the convenience of less frequent dosing. The presentinvention fulfills this need by providing exendin-4 molecules fused to amodified transferrin, which extends the in vivo circulatory half-life ofthe exendin-4 while maintaining bioactivity. Additionally, use of afusion protein of the invention may reduce the high incidence of nauseaand vomiting currently associated with use of incretins.

SUMMARY OF THE INVENTION

The invention provides fusion proteins comprising an exendin-4 fused toa transferrin (Tf) molecule via a peptide linker, preferably, anonhelical polypeptide linker.

Preferably, the linker is selected from the group consisting of PEAPTD(SEQ ID NO: 6), (PEAPTD)₂ (SEQ ID NO: 5), PEAPTD (SEQ ID NO: 6) incombination with an IgG hinge linker, and (PEAPTD)₂ (SEQ ID NO: 6) incombination with an IgG hinge linker. More preferably, the linker is(PEAPTD)₂ (SEQ ID NO: 5).

The Tf moiety of the fusion protein of the invention can originate fromany mammalian Tf, preferably, from human Tf. More preferably, the Tf ismodified (mTf) to exhibit reduced glycosylation as compared to a nativetransferrin molecule, and, even more preferably, the Tf has the aminoacid sequence as shown in SEQ ID NO: 17. In other preferred embodiments,the Tf is modified to reduce iron binding and/or binding to the Tfreceptor.

In another preferred embodiment, the N-terminus of the fusion proteinfurther comprises a secretion signal sequence, preferably, a signalsequence from serum transferrin, lactoferrin, melanotransferrin, or avariant thereof, more preferably, a human serum albumin (HSA)/MFα-1hybrid leader sequence, a modified HSA/MFα-1 hybrid leader sequence, ora Tf signal sequence, and, still more preferably, the signal sequence isthe human Tf signal sequence (nL) as shown in SEQ ID NO: 18.

In a preferred embodiment, the invention provides a fusion proteincomprising an exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein, wherein said fusion protein comprises the amino acid sequenceas shown in SEQ ID NO: 23 or SEQ ID NO: 25, the latter of which furthercomprises the nL leader sequence at the N-terminus. In other preferredembodiments, the exendin-4 is exendin-4(1-39) and has the amino acidsequence as shown in SEQ ID NO: 4, and/or the exendin-4 molecule isfused at the N-terminal end of the fusion protein, at the C-terminal endof the fusion protein or at both the N- and C-terminal ends of thefusion protein.

The invention also provides nucleic acid molecules encoding theabove-described fusion proteins, as well as the corresponding vectorscomprising the nucleic acid molecules, and host cells comprising thenucleic acid molecules and vectors.

Also featured by the invention is a pharmaceutical compositioncomprising any of the above-described fusion proteins and apharmaceutically acceptable carrier.

In preferred embodiments, the pharmaceutical composition comprises theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein of SEQ IDNO: 23, and, in some embodiments, the composition comprising theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein of SEQ IDNO: 23 is adapted to be administered at a dose ranging from about 0.5 mgto about 50 mg or from about 1 mg to about 100 mg.

In another preferred embodiment, the composition is adapted to beadministered via inhalation.

The invention also features a method of treating Type II diabetes orreducing blood glucose in a human patient in need thereof comprisingadministering to the patient a therapeutically effective amount of afusion protein comprising an exendin-4 fused to a Tf via a polypeptidelinker, preferably, a nonhelical linker.

Preferably, these methods comprise administering the exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein comprising the amino acidsequence as shown in SEQ ID NO: 23, and, in certain embodiments, thefusion protein as shown in SEQ ID NO: 23 is administered at a dose ofabout 0.5 mg to about 50 mg at a frequency of about once per week, onceper two weeks, or once per month. In another embodiment, the exendin-4fused to a Tf via a polypeptide linker, preferably, a nonhelical linker,and, more preferably, the fusion protein as shown in SEQ ID NO: 23, isadministered less frequently than exenatide to achieve therapeuticeffectiveness at an equivalent therapeutic dose.

The invention also features a method of treating obesity or reducingbody weight in a human patient in need thereof comprising administeringa therapeutically effective amount of a fusion protein comprising anexendin-4 fused to a Tf via a polypeptide linker, preferably, anonhelical linker. Preferably, the fusion protein comprises anexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein comprisingthe amino acid sequence as shown in SEQ ID NO: 23, and, in certainembodiments, the fusion protein as shown in SEQ ID NO: 23 isadministered at a dose of about 1 mg to about 100 mg at a frequency ofabout once per week, once per two weeks, or once per month. In anotherembodiment, the exendin-4 fused to a Tf via a polypeptide linker,preferably, the fusion protein as shown in SEQ ID NO: 23, isadministered less frequently than exenatide to achieve therapeuticeffectiveness.

The invention also provides for the use of an exendin-4/Tf fusionprotein, or a pharmaceutical composition comprising the exendin/Tffusion protein, preferably, an exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5)Tf fusion protein, and, more preferably, wherein the fusion protein isas shown in SEQ ID NO: 23, in the manufacture of a medicament fortreating Type II diabetes or for reducing blood glucose in a patient inneed thereof, preferably, wherein the medicament is adapted to beadministered at a dose of about 0.5 mg to about 50 mg, or in themanufacture of a medicament for treating obesity or reducing bodyweight, in a human patient in need thereof, preferably, wherein themedicament is adapted to be administered at a dose of about 1 mg toabout 100 mg.

By “exendin-4” is meant exendin-4 (1-39) as shown in SEQ ID NO: 4, aswell as an exendin-4 fragment having with up to 8 or 9 amino acidresidues removed from the C-terminal end of the sequence shown in SEQ IDNO: 4 to create, for example, an exendin-4(1-31) or exendin-4(1-30), aswell as peptides having at least 90%, and, preferably, at least 95%identity to exendin-4(1-39), or one of the other above-describedexendin-4 fragments.

As used herein, two or more DNA coding sequences are said to be “joined”or “fused” when, as a result of in-frame fusions between the DNA codingsequences, the DNA coding sequences are translated into a fusionpolypeptide. The phrase “joined” or “fused” can also be used to refer topeptides fused by alternative methods, for instance, chemical methods.The term “fusion” in reference to transferrin (Tf) fusions includes, butis not limited to, attachment of at least one therapeutic protein,polypeptide or peptide to the N-terminal end of Tf, attachment to theC-terminal end of Tf, and/or insertion between any two amino acidswithin Tf.

By “pharmaceutically acceptable” is meant a substance or compositionthat must be compatible chemically and/or toxicologically with the otheringredients comprising a formulation, and/or the mammal being treatedtherewith.

By “therapeutically effective amount” means an amount of an exendin-4/Tffusion protein of the present invention that reduces blood glucose,caloric intake, reduces body weight and/or reduces body fat with respectto appropriate control values determined prior to treatment or in avehicle-treated group.

The terms “treating”, “treat”, or “treatment” embrace both preventative,i.e., prophylactic, and palliative treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a graph showing collagenase resistance (MMP is matrixmetalloprotease 1) in vitro for the GLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQID NO: 5) mTf fusion protein (GLP-1/Tf). FIG. 1B is a graph showingcollagenase resistance for the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5)mTf fusion protein (exendin-4/Tf).

FIG. 2 is a graph showing the dose effect of the exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein (Exendin-4/Tf) on bloodglucose in diabetic (db/db) mice, and shows a comparative effect for theexendin-4 control. Each point represents the average glucose measurement(n=3).

FIG. 3 is a graph showing the dose effect of daily injections of theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein(Exendin-4/Tf) on body weight, and shows a comparative effect forexendin-4 and for the mTf controls.

FIG. 4 is a graph comparing the relative potency for the exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mil fusion protein (Exendin-4/Tf) andexendin-4. This was determined by a cell-based cAMP assay. The EC50 forthe exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein is 31.3pM and the EC50 for exendin-4 is 6.6 pM.

DETAILED DESCRIPTION OF THE INVENTION

Exendin-4/Tf Fusion Proteins

The exendin-4/Tf fusion protein of the present invention comprisesexendin-4 fused to a Tf peptide via a polypeptide linker. Preferably,the full length exendin-4 (1-39) (SEQ ID NO.: 4) is used, or anexendin-4 fragment, with up to 8 or 9 amino acid residues removed fromthe C-terminal end of the sequence shown in SEQ ID NO: 4 to create, forexample, an exendin-4 (1-31) or exendin-4(1-30).

Preferably, a non-helical polypeptide linker moiety is used to link theexendin-4 to the Tf.

The preferred linker is PEAPTDPEAPTD (SEQ ID NO: 5). Other linkers canbe selected from the group consisting of PEAPTD (SEQ ID NO.: 6), PEAPTD(SEQ ID NO.: 6) in combination with an IgG hinge linker (SEQ ID NOS:7-16), and PEAPTDPEAPTD (SEQ ID NO.: 5) in combination with an IgG hingelinker (SEQ ID NOS: 7-16). The fusion protein of the inventioncontaining a substantially non-helical linker moiety may exhibit anincreased productivity of expression as compared to a similar fusionprotein without a substantially non-helical linker. Further, anexendin-4/Tf fusion protein containing a substantially non-helicallinker may exhibit increased productivity of expression as compared to asimilar fusion protein with a helical polypeptide linker.

The preferred exendin-4/Tf fusion protein comprises exendin-4(1-39) (SEQID NO: 4) linked, via linker (PEAPTD)₂ (SEQ ID NO: 5), to the mTf asprovided in SEQ ID NO: 17. When produced, it is preferred that theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein alsocomprises the human transferrin secretion signal or leader sequence (nL)(SEQ ID NO: 18). The nucleic acid sequences encoding each of thecomponents of the preferred exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTffusion protein are as follows: nL leader sequence (SEQ ID NO: 19),exendin-4(1-39) (SEQ ID NO: 20), (PEAPTD)₂ (SEQ ID NO: 21), and the mTf(SEQ ID NO: 22). The amino acid sequence for the entire exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein, without the nL leader isSEQ ID NO: 23; its corresponding nucleic acid sequence is SEQ ID NO: 24.The amino acid sequence of the entire exendin-4(1-39) (PEAPTD)₂ (SEQ IDNO: 5) mTf fusion protein with the nL leader sequence at the N-terminusis SEQ ID NO: 25; its corresponding nucleic acid sequence is SEQ ID NO:26).

While the preferred mTf is described above, any transferrin may be usedto make the exendin-4/Tf fusion proteins of the invention. As anexample, the wild-type human Tf is a 679 amino acid protein ofapproximately 75 kDa (not accounting for glycosylation), with two maindomains or lobes, N (about 330 amino acids) and C (about 340 aminoacids), which appear to originate from a gene duplication. See GenBankaccession numbers NM_(—)001063, XM_(—)002793, M12530, XM_(—)039845,XM_(—)039847 and S95936, all of which are herein incorporated byreference in their entirety, as well as SEQ ID NOS: 2 and 3 (SEQ ID NO:2 comprises the additional 19 amino acid sequence of the nL humantransferrin leader sequence). The two domains have diverged over timebut retain a large degree of identity/similarity.

Each of the N and C lobes is further divided into two subdomains, N1 andN2, C1 and C2. The function of Tf is to transport iron to the cells ofthe body. This process is mediated by the Tf receptor (TfR), which isexpressed on all cells, particularly actively growing cells. TfRrecognizes the iron bound form of Tf (two molecules of which are boundper receptor), causing endocytosis whereby the TfR/Tf complex istransported to the endosome. The localized drop in pH in the endosomeresults in the release of bound iron and the recycling of the TfR/Tfcomplex to the cell surface and the release of Tf (known as apoTf in itsiron-unbound form). Receptor binding occurs via the C domain of Tf. Thetwo glycosylation sites in the C domain do not appear to be involved inreceptor binding because iron bound Tf that is not glycosylated doesbind the receptor.

Each Tf molecule can carry two iron ions (Fe³⁺). These are complexed inthe space between the N1 and N2, C1 and C2 sub domains resulting in aconformational change in the molecule.

For human transferrin of SEQ ID NO: 3, the iron binding sites compriseat least amino acids Asp 63 (Asp 82 of SEQ ID NO: 2 which includes thenative Tf signal sequence), Asp 392 (Asp 411 of SEQ ID NO: 2), Tyr 95(Tyr 114 of SEQ ID NO: 2), Tyr 426 (Tyr 445 of SEQ ID NO: 2), Tyr 188(Tyr 207 of SEQ ID NO: 2), Tyr 514 or 517 (Tyr 533 or Tyr 536 SEQ ID NO:2), His 249 (His 268 of SEQ ID NO: 2), and His 585 (His 604 of SEQ IDNO: 2). The hinge regions comprise at least N domain amino acid residues94-96, 245-247 and/or 316-318 as well as C domain amino acid residues425-427, 581-582 and/or 652-658 of SEQ ID NO: 3. The carbonate bindingsites of the human Tf of SEQ ID NO: 3 comprise at least amino acids Thr120 (Thr 139 of SEQ ID NO: 2), Thr 452 (Thr 471 of SEQ ID NO: 2), Arg124 (Arg 143 of SEQ ID NO: 2), Arg 456 (Arg 475 of SEQ ID NO: 2), Ala126 (Ala 145 of SEQ ID NO: 2), Ala 458 (Ala 477 of SEQ ID NO: 2), Gly127 (Gly 146 of SEQ ID NO: 2), and Gly 459 (Gly 478 of SEQ ID NO: 2).

Preferably, the modified exendin-4/Tf fusion protein is of human origin,although any animal Tf molecule may be used to produce the fusionproteins of the invention, including human Tf variants, cow, pig, sheep,dog, rabbit, rat, mouse, hamster, echnida, platypus, chicken, frog,hornworm, monkey, as well as other bovine, canine and avian species. Allof these Tf sequences are readily available in GenBank and other publicdatabases. The human Tf nucleic acid sequence is available (see SEQ IDNO: 1 and the accession numbers described above) and can be used to makegenetic fusions between Tf or a domain of Tf and the therapeuticmolecule of choice. Fusions may also be made from related molecules suchas lacto transferrin (lactoferrin) GenBank Acc: NM_(—)002343) or murinemelanotransferrin (GenBank Acc. NM_(—)013900).

Melanotransferrin is a glycosylated protein found at high levels inmalignant melanoma cells and was originally named human melanoma antigenp97 (Brown et al. 1982, Nature, 296: 171-173). It possesses highsequence homology with human serum transferrin, human lactoferrin, andchicken transferrin (Brown et al., Nature, 296: 171-173, 1982; Rose ofal., Proc. Natl. Acad. Sci. USA, 83: 1261-1265, 1986). However, unlikethese receptors, no cellular receptor has been identified formelanotransferrin. Melanotransferrin reversibly binds iron and it existsin two forms, one of which is bound to cell membranes by a glycosylphosphatidylinositol anchor while the other form is both soluble andactively secreted (Baker et al., FEBS Lett, 298, 1992: 215-218; Alemanyet al., J. Cell Sci., 104: 1155-1162, 1993; Food et al., J. Biol. Chem.274: 7011-7017, 1994).

Lactoferrin (Lf), a natural defense iron-binding protein, has been foundto possess antibacterial, antimycotic, antiviral, antineoplastic andanti-inflammatory activity. The protein is present in exocrinesecretions that are commonly exposed to normal flora: milk, tears, nasalexudate, saliva, bronchial mucus, gastrointestinal fluids,cervico-vaginal mucus and seminal fluid. Additionally, Lf is a majorconstituent of the secondary specific granules of circulatingpolymorphonuclear neutrophils (PMNs). The apoprotein is released ondegranulation of the PMNs in septic areas. A principal function of Lf isthat of scavenging free iron in fluids and inflamed areas so as tosuppress free radical-mediated damage and decrease the availability ofthe metal to invading microbial and neoplastic cells. In a study thatexamined the turnover rate of ¹²⁵I Lf in adults, it was shown that Lf israpidly taken up by the liver and spleen, and the radioactivitypersisted for several weeks in the liver and spleen (Bennett et al.,Clin. Sci. (Lond.) 57: 453-460, 1979).

The transferrin portion of the exendin-4/Tf fusion protein of theinvention includes a transferrin splice variant. In one example, atransferrin splice variant can be a splice variant of human transferrin.Specifically, the human transferrin splice variant can be that ofGenbank Accession AAA61140.

The transferrin portion of the exendin-4/Tf fusion protein of theinvention includes a lactoferrin splice variant. In one example, a humanserum lactoferrin splice variant can be a novel splice variant of aneutrophil lactoferrin. Specifically, the neutrophil lactoferrin splicevariant can be that of the sequence displayed in Genbank AccessionAAA59479. Also, the neutrophil lactoferrin splice variant can comprisethe following amino acid sequence EDCIALKGEADA (SEQ ID NO: 27), whichincludes the novel region of splice-variance.

Alternatively, the transferrin portion of the exendin-4/Tf fusionprotein of the invention includes a melanotransferrin variant.

Modified Tf fusions may be made with any Tf protein, fragment, domain,or engineered domain. For instance, fusion proteins may be producedusing the full-length Tf sequence, with or without the native Tf signalsequence. Tf fusion proteins may also be made using a single Tf domain,such as an individual N or C domain or a modified form of Tf comprising2N or 2C domains (see U.S. Pat. Appl. Publ. No. US 2006/0130158).Fusions of a therapeutic protein to a single C domain may be produced,wherein the C domain is altered to reduce inhibit or preventglycosylation. Alternatively, the use of a single N domain isadvantageous as the Tf glycosylation sites reside in the C domain andthe N domain. Preferably, the Tf fusion protein has a single N domainwhich is expressed at a high level.

As used herein, a C terminal domain or lobe modified to function as anN-like domain is modified to exhibit glycosylation patterns or ironbinding properties substantially like that of a native or wild-type Ndomain or lobe. Preferably, the C domain or lobe is modified so that itis not glycosylated and does not bind iron by substitution of therelevant C domain regions or amino acids to those present in thecorresponding regions or sites of a native or wild-type N domain.

As used herein, a Tf moiety comprising “two N domains or lobes” includesa Tf molecule that is modified to replace the native C domain or lobewith a native or wild-type N domain or lobe or a modified N domain orlobe or contains a C domain that has been modified to functionsubstantially like a wild-type or modified N domain.

Analysis of the two domains by overlay of the two domains (Swiss PDBViewer 3.7b2, Iterative Magic Fit) and by direct amino acid alignment(ClustalW multiple alignment) reveals that the two domains have divergedover time. Amino acid alignment shows 42% identity and 59% similaritybetween the two domains. However, approximately 80% of the N domainmatches the C domain for structural equivalence. The C domain also hasseveral extra disulfide bonds compared to the N domain.

In one embodiment, the transferrin portion of the exendin-4/Tf fusionprotein includes at least two N terminal lobes of transferrin. Infurther embodiments, the transferrin portion of the exendin-4/Tf fusionprotein includes at least two N terminal lobes of transferrin derivedfrom human serum transferrin.

The transferrin portion of the exendin-4/Tf fusion protein can alsoinclude: at least two N terminal lobes of transferrin having a mutationin at least one amino acid residue selected from the group consisting ofAsp63, Gly65, Tyr95, Tyr188, and His249 of SEQ ID NO: 3; a recombinanthuman serum transferrin N-terminal lobe mutant having a mutation atLys206 or His207 of SEQ ID NO: 3; or at least two C terminal lobes oftransferrin. In further embodiments, the transferrin portion of theexendin-4/Tf fusion protein includes at least two C terminal lobes oftransferrin derived from human serum transferrin.

In a further embodiment, the C terminal lobe mutant further includes amutation of at least one of Asn413 and Asn611 of SEQ ID NO: 3 which doesnot allow glycosylation.

In another embodiment, the transferrin portion of the exendin-4/Tffusion protein includes at least two C terminal lobes of transferrinhaving a mutation in at least one amino acid residue selected from thegroup consisting of Asp392, Tyr426, Tyr514, Tyr517 and His585 of SEQ IDNO: 3, wherein the mutant retains the ability to bind metal. In analternate embodiment, the transferrin portion of the exendin-4/Tf fusionprotein includes at least two C terminal lobes of transferrin having amutation in at least one amino acid residue selected from the groupconsisting of Tyr426, Tyr514, Tyr517 and His585 of SEQ ID NO: 3, whereinthe mutant has a reduced ability to bind metal. In another embodiment,the transferrin portion of the exendin-4/Tf fusion protein includes atleast two C terminal lobes of transferrin having a mutation in at leastone amino acid residue selected from the group consisting of Asp392,Tyr426, Tyr517 and His585 of SEQ ID NO:3, wherein the mutant does notretain the ability to bind metal and functions substantially like an Ndomain.

When the C domain of Tf is part of the fusion protein, the two N-linkedglycosylation sites, amino acid residues corresponding to N413 and N611of SEQ ID NO: 3 may be mutated for expression in a yeast system toprevent glycosylation or hypermannosylationn and extend the serumhalf-life of the fusion protein and/or therapeutic protein (to produceasialo-, or in some instances, monosialo-Tf or disialo-Tf). In additionto Tf amino acids corresponding to N413 and N611, mutations may be tothe adjacent residues within the N-X-S/T glycosylation site to preventor substantially reduce glycosylation. See U.S. Pat. No. 5,986,067. Ithas also been reported that the N domain of Tf expressed in Pichiapastoris becomes O-linked glycosylated with a single hexose at S32 whichalso may be mutated or modified to prevent such glycosylation.

Accordingly, the exendin-4/Tf fusion protein can also include a modifiedtransferrin molecule wherein the transferrin exhibits reducedglycosylation, including but not limited to asialo-, monosialo- anddisialo-forms of Tf. In another embodiment, the transferrin portion ofthe exendin-4/Tf fusion protein includes a recombinant transferrinmutant that is mutated to prevent glycosylation. The transferrin portionof the exendin-4/Tf fusion protein can also include a recombinanttransferrin mutant that is fully glycosylated. In a further embodiment,the transferrin portion of the exendin-4/Tf fusion protein includes arecombinant human serum transferrin mutant that is mutated to preventN-linked glycosylation, wherein at least one of Asn413 and Asn611 of SEQID NO: 3 is mutated to an amino acid which does not allow glycosylation.In another embodiment, the transferrin portion of the exendin-4/Tffusion protein includes a recombinant human serum transferrin mutantthat is mutated to prevent or substantially reduce glycosylation,wherein, for example, mutations are made to the adjacent residues withinthe N-X-S/T glycosylation site, for instance mutation of the S/Tresidues. Moreover, glycosylation may be reduced or prevented bymutating the serine or threonine residue. Further, changing the X toproline is known to inhibit glycosylation.

As discussed below in more detail, modified Tf fusion proteins of theinvention may also be engineered to not bind iron and/or bind the Tfreceptor. In other embodiments of the invention, the iron binding isretained and the iron binding ability of Tf may be used to deliver atherapeutic protein or peptide(s) to the inside of a cell, across anepithelial or endothelial cell membrane. These embodiments that bindiron and/or the Tf receptor will often be engineered to reduce orprevent glycosylation to extend the serum half-life of the therapeuticprotein. The N domain alone will not bind to TfR when loaded with iron,and the iron bound C domain will bind TfR but not with the same affinityas the whole molecule.

Alternatively, the transferrin portion of the exendin-4/Tf fusionprotein can include a recombinant transferrin mutant having a mutationwherein the mutant does not retain the ability to bind metal ions. In analternate embodiment, the transferrin portion of the exendin-4/Tf fusionprotein includes a recombinant transferrin mutant having a mutationwherein the mutant has a weaker binding affinity for metal ions thanwild-type serum transferrin. In an alternate embodiment, the transferrinportion of the exendin-4/Tf fusion protein includes a recombinanttransferrin mutant having a mutation wherein the mutant has a strongerbinding affinity for metal ions than wild-type serum transferrin.

In another embodiment, the transferrin portion of the exendin-4/Tffusion protein includes a recombinant transferrin mutant having amutation wherein the mutant does not retain the ability to bind to thetransferrin receptor. For instance, the exendin-4 and Tf fusion proteinsof the invention may bind a cell surface GLP-1 receptor but not a Tfreceptor. Such fusion proteins can be therapeutically active at the cellsurface, i.e., without entering the cell.

Alternatively, the transferrin portion of the exendin-4/Tf fusionprotein can include: a recombinant transferrin mutant having a mutationwherein the mutant has a weaker binding affinity for the transferrinreceptor than wild-type serum transferrin; a recombinant transferrinmutant having a mutation wherein the mutant has a stronger bindingaffinity for the transferrin receptor than wild-type serum transferrin;a recombinant transferrin mutant having a mutation wherein the mutantdoes not retain the ability to bind to carbonate ions; a recombinanttransferrin mutant having a mutation wherein the mutant has a weakerbinding affinity for carbonate ions than wild-type serum transferrin; ora recombinant transferrin mutant having a mutation wherein the mutanthas a stronger binding affinity for carbonate ions than wild-type serumtransferrin.

In another embodiment, the transferrin portion of the exendin-4/Tffusion protein includes a recombinant human serum transferrin mutanthaving a mutation in at least one amino acid residue selected from thegroup consisting of Asp63, Gly65, Tyr95, Tyr188, His249, Asp392, Tyr426,Tyr514, Tyr517 and His585 of SEQ ID NO: 3, wherein the mutant retainsthe ability to bind metal ions. In an alternate embodiment, arecombinant human serum transferrin mutant has a mutation in at leastone amino acid residue selected from the group consisting of Asp63,Gly65, Tyr95, Tyr188, His249, Asp392, Tyr426, Tyr514, Tyr517 and His585of SEQ ID NO: 3, wherein the mutant has a reduced ability to bind metalions. In another embodiment, a recombinant human serum transferrinmutant having a mutation in at least one amino acid residue selectedfrom the group consisting of Asp63, Gly65, Tyr95, Tyr188, His249,Asp392, Tyr426, Tyr517 and His585 of SEQ ID NO: 3, wherein the mutantdoes not retain the ability to bind metal ions.

In another embodiment, the transferrin portion of the exendin-4/Tffusion protein includes a recombinant human serum transferrin mutanthaving a mutation at Lys206 or His207 of SEQ ID NO:3, wherein the mutanthas a stronger binding affinity for metal ions than wild-type humanserum transferrin (see U.S. Pat. No. 5,986,067). In an alternateembodiment, the transferrin portion of the exendin-4/Tf fusion proteinincludes a recombinant human serum transferrin mutant having a mutationat Lys206 or His207 of SEQ ID NO:3, wherein the mutant has a weakerbinding affinity for metal ions than wild-type human serum transferrin.In a further embodiment, the transferrin portion of the exendin-4/Tffusion protein includes a recombinant human serum transferrin mutanthaving a mutation at Lys206 or His207 of SEQ ID NO:3, wherein the mutantdoes not bind metal ions.

Any available technique may be used to produce the exendin-4/Tf fusionproteins of the invention, including but not limited to moleculartechniques commonly available, for instance, those disclosed in Sambrooket al. Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold SpringHarbor Laboratory Press, 1989. When carrying out nucleotidesubstitutions using techniques for accomplishing site-specificmutagenesis that are well known in the art, the encoded amino acidchanges are preferably of a minor nature, that is, conservative aminoacid substitutions, although other, non-conservative, substitutions arecontemplated as well, particularly when producing a modified transferrinportion of a Tf fusion protein, e.g., a modified Tf protein exhibitingreduced glycosylation, reduced iron binding and the like. Specificallycontemplated are amino acid substitutions, small deletions orinsertions, typically of one to about 30 amino acids; insertions betweentransferrin domains; small amino- or carboxyl-terminal extensions, suchas an amino-terminal methionine residue, or small linker peptides ofless than 50, 40, 30, 20 or 10 residues between transferrin domains orlinking a transferrin protein and an exendin-4 or a small extension thatfacilitates purification, such as a poly-histidine tract, an antigenicepitope or a binding domain.

Examples of conservative amino acid substitutions are substitutions madewithin the same group such as within the group of basic amino acids(such as arginine, lysine, histidine), acidic amino acids (such asglutamic acid and aspartic acid), polar amino acids (such as glutamineand asparagine), hydrophobic amino acids (such as leucine, isoleucine,valine), aromatic amino acids (such as phenylalanine, tryptophan,tyrosine) and small amino acids (such as glycine, alanine, serine,threonine, methionine).

Non-conservative substitutions encompass substitutions of amino acids inone group by amino acids in another group. For example, anon-conservative substitution would include the substitution of a polaramino acid for a hydrophobic amino acid. For a general description ofnucleotide substitution, see e.g. Ford et al., Prot. Exp. Pur. 2:95-107, 1991. Non-conservative substitutions, deletions and insertionsare particularly useful to produce Tf fusion proteins of the inventionthat exhibit no or reduced binding of iron, no or reduced binding of thefusion protein to the Tf receptor and/or no or reduced glycosylation.

Iron binding and/or receptor binding may be reduced or disrupted bymutation, including deletion, substitution or insertion into, amino acidresidues corresponding to one or more of Tf N domain residues Asp63,Tyr95, Tyr188, His249 and/or C domain residues Asp 392, Tyr 426, Tyr 514and/or His 585 of SEQ ID NO: 3. Iron binding may also be affected bymutation to amino acids Lys206, His207 or Arg632 of SEQ ID NO: 3.Carbonate binding may be reduced or disrupted by mutation, includingdeletion, substitution or insertion into, amino acid residuescorresponding to one or more of Tf N domain residues Thr120, Arg124.Ala126, Gly 127 and/or C domain residues Thr 452, Arg 456, Ala 458and/or Gly 459 of SEQ ID NO: 3. A reduction or disruption of carbonatebinding may adversely affect iron and/or receptor binding.

Binding to the Tf receptor may be reduced or disrupted by mutation,including deletion, substitution or insertion into, amino acid residuescorresponding to one or more of Tf N domain residues described above foriron binding.

As discussed above, glycosylation may be reduced or prevented bymutation, including deletion, substitution or insertion into, amino acidresidues corresponding to one or more of Tf C domain residues around theN-X-S/T sites corresponding to C domain residues N413 and/or N611 (SeeU.S. Pat. No. 5,986,067). For instance, the N413 and/or N611 may bemutated to Glu residues.

In instances where the Tf fusion proteins of the invention are notmodified to prevent glycosylation, iron binding, carbonate bindingand/or receptor binding, glycosylation, iron and/or carbonate ions maybe stripped from or cleaved off of the fusion protein. For instance,available deglycosylases may be used to cleave glycosylation residuesfrom the fusion protein, in particular the sugar residues attached tothe Tf portion, yeast deficient in glycosylation enzymes may be used toprevent glycosylation and/or recombinant cells may be grown in thepresence of an agent that prevents glycosylation, e.g., tunicamycin.

The carbohydrates on the fusion protein may also be reduced orcompletely removed enzymatically by treating the fusion protein withdeglycosylases. Deglycosylases are well known in the art. Examples ofdeglycosylases include but are not limited to galactosidase, PNGase A,PNGase F, glucosidase, mannosidase, fucosidase, and Endo Hdeglycosylase.

Nevertheless, in certain circumstances, it may be preferable for oraldelivery that the Tf portion of the fusion protein be fullyglycosylated.

Additional mutations may be made with Tf to alter the three dimensionalstructure of Tf, such as modifications to the hinge region to preventthe conformational change needed for iron binding and Tf receptorrecognition. For instance, mutations may be made in or around N domainamino acid residues 94-96, 245-247 and/or 316-318 as well as C domainamino acid residues 425-427, 581-582 and/or 652-658. In addition,mutations may be made in or around the flanking regions of these sitesto alter Tf structure and function.

The exendin-4/Tf fusion protein can function as a carrier protein toextend the half life or bioavailability of the therapeutic protein aswell as, in some instances, delivering the therapeutic protein inside acell and/or across the blood-brain barrier (BBB). In an alternateembodiment, the fusion protein includes a modified transferrin moleculewherein the transferrin does not retain the ability to cross the BBB.

In another embodiment, the exendin-4/Tf fusion protein includes amodified transferrin molecule wherein the transferrin molecule retainsthe ability to bind to the transferrin receptor and transport thetherapeutic peptide inside cells. In an alternate embodiment, theexendin-4/Tf fusion protein includes a modified transferrin moleculewherein the transferrin molecule does not retain the ability to bind tothe transferrin receptor and transport the therapeutic peptide insidecells.

In further embodiments, the exendin-4/Tf fusion protein includes amodified transferrin molecule wherein the transferrin molecule retainsthe ability to bind to the transferrin receptor and transport thetherapeutic peptide inside cells and retains the ability to cross theBBB. In an alternate embodiment, the exendin-4/Tf fusion proteinincludes a modified transferrin molecule wherein the transferrinmolecule retains the ability to cross the BBB, but does not retain theability to bind to the transferrin receptor and transport thetherapeutic peptide inside cells.

The modified fusion proteins of the present invention can be composed ofamino acids joined to each other by peptide bonds or modified peptidebonds and may contain amino acids other than the 20 gene-encoded aminoacids. The polypeptides may be modified by either natural processes,such as post-translational processing, or by chemical modificationtechniques which are well known in the art. Such modifications are welldescribed in basic texts and in more detailed monographs, as well as ina voluminous research literature.

Modifications can occur anywhere in a polypeptide, including the peptidebackbone, the amino acid side-chains and the amino or carboxy termini.It will be appreciated that the same type of modification may be presentin the same or varying degrees at several sites in a given polypeptide.Also, a given polypeptide may contain many types of modifications.Polypeptides may be branched, for example, as a result ofubiquitination, and they may be cyclic, with or without branching.Cyclic, branched, and branched cyclic polypeptides may result fromposttranslation natural processes or may be made by synthetic methods.Modifications include acetylation, acylation, ADP-ribosylation,amidation, covalent attachment of flavin, covalent attachment of a hememoiety, covalent attachment of a nucleotide or nucleotide derivative,covalent attachment of a lipid or lipid derivative, covalent attachmentof phosphotidylinositol, cross-linking, cyclization, disulfide bondformation, demethylation, formation of covalent cross-links, formationof cysteine, glycosylation, GPI anchor formation, hydroxylation,iodination, methylation, myristylation, oxidation, pegylation,proteolytic processing, phosphorylation, prenylation, racemization,sulfation, transfer-RNA mediated addition of amino acids to proteinssuch as arginylation, and ubiquitination. (See, e.g., Proteins—Structureand Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman andCompany, New York, 1993; Post-translational Covalent Modification ofProteins, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12, 1983;and Seifter et al. Meth. Enzymol. 182:626-646, 1990).

Nucleic Acid Molecules Encoding Exendin-4/Tf

The present invention also provides nucleic acid molecules encoding theexendin-4/Tf fusion proteins. A preferred nucleic acid molecule encodesSEQ ID NO: 23, which is the amino acid sequence of exendin-4(1-39),linked by (PEAPTD)₂ (SEQ ID NO: 5), to an mTf. An exemplary nucleic acidsequence is shown as SEQ ID NO: 24. Most preferably, the nucleic acidsequence of the present invention encodes SEQ ID NO: 25, which is theamino acid sequence of exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTffusion protein plus an additional N-terminal 19 amino acids representingthe human transferrin secretion signal or leader sequence. An exemplarynucleic acid sequence encoding SEQ ID NO: 25 is shown as SEQ ID NO: 26.

Sequences that encode an exendin-4/Tf fusion protein can also include astop codon (e.g., tga, taa, tag) at the C-terminal end, and can readilybe obtained in a variety of ways including, without limitation, chemicalsynthesis, genetic mutation of wild type exendin-4 and transferrinpolynucleotide sequences obtained from cDNA or genomic libraryscreening, expression library screening, and/or polymerase chainreaction (PCR) amplification of cDNA. Nucleic acid molecules encoding anexendin-4/Tf fusion protein may be produced using site directedmutagenesis, PCR amplification, or other appropriate methods, where theprimer(s) have the desired point mutations. Recombinant DNA methods andmutagenesis methods described herein are generally those set forth inSambrook et al., Molecular Cloning: A Laboratory Manual, Cold SpringHarbor Laboratory Press, 1989, and Current Protocols in MolecularBiology, Ausubel at al., Green Publishers Inc. and Wiley and Sons, 1994.

Nucleic acid polynucleotides encoding the amino acid sequence anexendin-4/Tf fusion protein may be identified by expression cloningwhich employs the detection of positive clones based upon a property ofthe expressed protein. Typically, nucleic acid libraries are screened bythe binding of an antibody or other binding partner (e.g., receptor orligand) to cloned proteins that are expressed and displayed on a hostcell surface. The antibody or binding partner is modified with adetectable label to identify those cells expressing the desired clone.

Recombinant expression techniques conducted in accordance with thedescriptions set forth below may be followed to produce exendin-4/Tffusion protein encoding polynucleotides and to express the encodedpolypeptides. For example, by inserting a nucleic acid sequence thatencodes the amino acid sequence of an exendin-4/Tf fusion protein intoan appropriate vector, one skilled in the art can readily produce largequantities of the desired nucleotide sequence. The sequences can then beused to generate detection probes or amplification primers.Alternatively, a polynucleotide encoding the amino acid sequence of anexendin-4/Tf fusion protein can be inserted into an expression vector.By introducing the expression vector into an appropriate host, theencoded exendin-4/Tf fusion protein may be produced in large amounts.

Another method for obtaining a suitable nucleic acid sequence is thepolymerase chain reaction (PCR). In this method, cDNA is prepared frompoly(A)+RNA or total RNA using the enzyme reverse transcriptase. Twoprimers, typically complementary to two separate regions of cDNAencoding the amino acid sequence of an exendin-4/Tf fusion protein, arethen added to the cDNA along with a polymerase such as Taq polymerase,and the polymerase amplifies the cDNA region between the two primers.

The DNA fragment encoding the amino-terminus of the polypeptide can havean ATG, which encodes a methionine residue. This methionine may or maynot be present on the mature form of the exendin-4/Tf fusion protein,depending on whether the polypeptide produced in the host cell isdesigned to be secreted from that cell. The codon encoding isoleucinecan also be used as a start site. Other methods known to the skilledartisan may be used as well. In certain embodiments, nucleic acidvariants contain codons which have been altered for optimal expressionof an exendin-4/Tf fusion protein in a given host cell. Particular codonalterations will depend upon the exendin-4/Tf fusion protein and thehost cell selected for expression. Such codon optimization can becarried out by a variety of methods, for example, by selecting codonswhich are preferred for use in highly expressed genes in a given hostcell. Computer algorithms which incorporate codon frequency tables suchas “Eco_high.Cod” for codon preference of highly expressed bacterialgenes may be used and are provided by the University of WisconsinPackage Version 9.0 (Genetics Computer Group, Madison, Wis.). Otheruseful codon frequency tables include “Celegans_high.cod,”“Celegans_low.cod,” “Drosophila_high.cod,” “Human_high.cod,”“Maize_high.cod,” and “Yeast_high.cod.”

Vectors

A nucleic acid molecule encoding the amino acid sequence of anexendin-4/Tf fusion protein is inserted into an appropriate expressionvector using standard ligation techniques. The vector is typicallyselected to be functional in the particular host cell employed (i.e.,the vector is compatible with the host cell machinery such thatamplification of the gene and/or expression of the gene can occur). Anucleic acid molecule encoding the amino acid sequence of anexendin-4/Tf fusion protein may be amplified/expressed in prokaryotic,yeast, insect (baculovirus systems) and/or eukaryotic host cells. For areview of expression vectors, see Meth. Enz., vol. 185, D. V. Goeddel,Academic Press, 1990.

Typically, expression vectors used in any of the host cells will containsequences for plasmid maintenance and for cloning and expression ofexogenous nucleotide sequences. Such sequences, collectively referred toas “flanking sequences” in certain embodiments, will typically includeone or more of the following nucleotide sequences: a promoter, one ormore enhancer sequences, an origin of replication, a transcriptionaltermination sequence, a complete intron sequence containing a donor andacceptor splice site, a sequence encoding a leader sequence forpolypeptide secretion, a ribosome binding site, a polyadenylationsequence, a polylinker region for inserting the nucleic acid encodingthe polypeptide to be expressed, and a selectable marker element. Eachof these sequences is discussed below.

Optionally, the vector may contain a “tag”-encoding sequence, i.e., anoligonucleotide molecule located at the 5′ or 3′ end of an exendin-4/Tffusion protein coding sequence; the oligonucleotide sequence encodespolyHis (such as hexaHis), or another “tag” such as FLAG, HA(hemaglutinin influenza virus), or myc for which commercially availableantibodies exist. This tag is typically fused to the polypeptide uponexpression of the polypeptide, and can serve as a means for affinitypurification of the exendin-4/Tf fusion protein from the host cell.Affinity purification can be accomplished, for example, by columnchromatography using antibodies against the tag as an affinity matrix.Optionally, the tag can subsequently be removed from the purifiedexendin-4/Tf fusion protein by various means such as using certainpeptidases for cleavage, e.g., enterokinase digestion 3′ of a FLAG tagsequence that is upstream of the one of the amino acid sequences.

Flanking sequences may be homologous (i.e., from the same species and/orstrain as the host cell), heterologous (i.e., from a species other thanthe host cell species or strain), hybrid (i.e., a combination offlanking sequences from more than one source), or synthetic, or theflanking sequences may be native sequences which normally function toregulate exendin-4 expression. The source of a flanking sequence may beany prokaryotic or eukaryotic organism, any vertebrate or invertebrateorganism, or any plant, provided that the flanking sequence isfunctional in, and can be activated by, the host cell machinery.

Useful flanking sequences may be obtained by any of several methods wellknown in the art. Typically, flanking sequences useful herein will havebeen previously identified by mapping and/or by restriction endonucleasedigestion and can thus be isolated from the proper tissue source usingthe appropriate restriction endonucleases. In some cases, the fullnucleotide sequence of a flanking sequence may be known. Here, theflanking sequence may be synthesized using the methods described hereinfor nucleic acid synthesis or cloning.

Where all or only a portion of the flanking sequence is known, it may beobtained using PCR and/or by screening a genomic library with a suitableoligonucleotide and/or flanking sequence fragment from the same oranother species. Where the flanking sequence is not known, a fragment ofDNA containing a flanking sequence may be isolated from a larger pieceof DNA that may contain, for example, a coding sequence or even anothergene or genes. Isolation may be accomplished by restriction endonucleasedigestion to produce the proper DNA fragment followed by isolation usingagarose gel purification, Qiagen® column chromatography (Qiagen,Chatsworth, Calif.), or other methods known to the skilled artisan. Theselection of suitable enzymes to accomplish this purpose will be readilyapparent to one of skill in the art.

An origin of replication is typically a part of those prokaryoticexpression vectors purchased commercially, and the origin aids in theamplification of the vector in a host cell. Amplification of the vectorto a certain copy number can, in some cases, be important for theoptimal expression of an exendin-4/Tf fusion protein. If the vector ofchoice does not contain an origin of replication site, one may bechemically synthesized based on a known sequence, and ligated into thevector. For example, the origin of replication from the plasmid pBR322(New England Biolabs, Beverly, Mass.) is suitable for most gram-negativebacteria and various origins (e.g., SV40, polyoma, adenovirus, vesicularstomatitis virus (VSV), or papillomaviruses such as HPV or BPV) areuseful for cloning vectors in mammalian cells. Generally, the origin ofreplication component is not needed for mammalian expression vectors(for example, the SV40 origin is often used only because it contains theearly promoter).

A transcription termination sequence is typically located 3′ of the endof a polypeptide coding region and serves to terminate transcription.Usually, a transcription termination sequence in prokaryotic cells is aG-C rich fragment followed by a poly-T sequence. While the sequence iseasily cloned from a library or even purchased commercially as part of avector, it can also be readily synthesized using methods for nucleicacid synthesis such as those described herein.

A selectable marker gene element encodes a protein necessary for thesurvival and growth of a host cell grown in a selective culture medium.Typical selection marker genes encode proteins that (a) conferresistance to antibiotics or other toxins, e.g., ampicillin,tetracycline, or kanamycin for prokaryotic host cells; (b) complementauxotrophic deficiencies of the cell; or (c) supply critical nutrientsnot available from complex media. Preferred selectable markers are thekanamycin resistance gene, the ampicillin resistance gene, and thetetracycline resistance gene. A neomycin resistance gene may also beused for selection in prokaryotic and eukaryotic host cells.

Other selection genes may be used to amplify the gene that will beexpressed. Amplification is the process wherein genes that are ingreater demand for the production of a protein critical for growth arereiterated in tandem within the chromosomes of successive generations ofrecombinant cells. Examples of suitable selectable markers for mammaliancells include dihydrofolate reductase (DHFR) and thymidine kinase. Themammalian cell transformants are placed under selection pressure whereinonly the transformants are uniquely adapted to survive by virtue of theselection gene present in the vector. Selection pressure is imposed byculturing the transformed cells under conditions in which theconcentration of selection agent in the medium is successively changed,thereby leading to the amplification of both the selection gene and theDNA that encodes an exendin-4/Tf fusion protein. As a result, increasedquantities of an exendin-4/Tf fusion protein are synthesized from theamplified DNA.

A ribosome binding site is usually necessary for translation initiationof mRNA and is characterized by a Shine-Dalgarno sequence (prokaryotes)or a Kozak sequence (eukaryotes). The element is typically located 3′ tothe promoter and 5′ to the coding sequence of the exendin-4/Tf fusionprotein to be expressed. The Shine-Dalgarno sequence is varied but istypically a polypurine (i.e., having a high A-G content). ManyShine-Dalgarno sequences have been identified, each of which can bereadily synthesized using methods set forth herein and used in aprokaryotic vector.

The terms “secretory signal sequence” or “signal sequence” or “secretionleader sequence” are used interchangeably and are described, forexample, in U.S. Pat. Nos. 6,291,212 and 5,547,871. Secretory signalsequences or signal sequences or secretion leader sequences encodesecretory peptides. A secretory peptide is an amino acid sequence thatacts to direct the secretion of a mature polypeptide or protein from acell. Secretory peptides are generally characterized by a core ofhydrophobic amino acids and are typically (but not exclusively) found atthe amino termini of newly synthesized proteins. Very often thesecretory peptide is cleaved from the mature protein during secretion.Secretory peptides may contain processing sites that allow cleavage ofthe signal peptide from the mature protein as it passes through thesecretory pathway. Processing sites may be encoded within the signalpeptide or may be added to the signal peptide by, for example, in vitromutagenesis.

Secretory peptides may be used to direct the secretion of the fusionproteins of the invention. One such secretory peptide that may be usedin combination with other secretory peptides is the alpha mating factorleader sequence. Secretory signal sequences or signal sequences orsecretion leader sequences are required for a complex series ofpost-translational processing steps which result in secretion of aprotein. If an intact signal sequence is present, the protein beingexpressed enters the lumen of the rough endoplasmic reticulum and isthen transported through the Golgi apparatus to secretory vesicles andis finally transported out of the cell. Generally, the signal sequenceimmediately follows the initiation codon and encodes a signal peptide atthe amino-terminal end of the protein to be secreted. In most cases, thesignal sequence is cleaved off by a specific protease, called a signalpeptidase. Preferred signal sequences improve the processing and exportefficiency of recombinant protein expression using viral, mammalian oryeast expression vectors.

In one embodiment, the native Tf signal sequence may be used to expressand secrete fusion proteins of the present invention. Since transferrinmolecules exist in various types of secretions such as blood, tears, andmilk, there are many different transferrin signal peptides. For example,the transferrin signal peptide could be from serum transferrin,lactotransferrin, or melanotransferrin. The native transferrin signalpeptide also could be from various species such as insects, mammals,fish, frog, duck, chicken, or other species. Preferably, the signalpeptide is from a mammalian transferrin molecule. More preferably, thesignal peptide is from human serum transferrin. The signal peptidesequences from various mammalian transferrin molecules are described inU.S. Pat. Appl. Publ. No. 2006/0205037.

Preferably, the transferrin derived signal sequence may be used tosecrete a heterologous protein, for instance, any protein of interestthat is heterologous to the Tf signal sequence may be expressed andsecreted using a Tf signal. In particular, a Tf signal sequence may beused to secrete proteins from recombinant yeast. Preferably, the signalpeptide is from human serum transferrin (SEQ ID NO: 18; encoded by SEQID NO: 19). Other preferred signal peptides include HSA/MFα-1 (SEQ IDNO: 40; encoded by SEQ ID NO: 41), and modified HSA/MFα-1 (SEQ ID NO:42; encoded by SEQ ID NO: 43).

In order to ensure efficient removal of the signal sequence, in somecases it may be preferable to include a short pro-peptide sequencebetween the signal sequence and the mature protein in which theC-terminal portion of the pro-peptide comprises a recognition site for aprotease, such as the yeast kex2p protease. Preferably, the pre-peptidesequence is about 2-12 amino acids in length, more preferably about 4-8amino acids in length. Examples of such pro-peptides areArg-Ser-Leu-Asp-Lys-Arg (SEQ ID NO: 44), Arg-Ser-Leu-Asp-Arg-Arg (SEQ IDNO: 45), Arg-Ser-Leu-Glu-Lys-Arg (SEQ ID NO: 46), andArg-Ser-Leu-Glu-Arg-Arg (SEQ ID NO: 47).

Expression and cloning vectors will typically contain a promoter that isrecognized by the host organism and operably linked to the moleculeencoding the exendin-4/Tf fusion protein. Promoters are untranscribedsequences located upstream (i.e., 5′) to the start codon of a structuralgene (generally within about 100 to 1000 bp) that control thetranscription of the structural gene. Promoters are conventionallygrouped into one of two classes: inducible promoters and constitutivepromoters. Inducible promoters initiate increased levels oftranscription from DNA under their control in response to some change inculture conditions, such as the presence or absence of a nutrient or achange in temperature. Constitutive promoters, on the other hand,initiate continual gene product production; that is, there is little orno control over gene expression. A large number of promoters, recognizedby a variety of potential host cells, are well known. A suitablepromoter is operably linked to the DNA encoding an exendin-4/Tf fusionprotein by removing the promoter from the source DNA by restrictionenzyme digestion and inserting the desired promoter sequence into thevector. The native exendin-4 or transferrin promoter sequence may beused to direct amplification and/or expression of an exendin-4/Tf fusionprotein nucleic acid molecule. However, a heterologous promoter ispreferred, if it permits greater transcription and higher yields of theexpressed protein as compared to the native promoter, and if it iscompatible with the host cell system that has been selected for use.

Suitable promoters for use with yeast hosts are also well known in theart and are further discussed below. Yeast enhancers are advantageouslyused with yeast promoters. Suitable promoters for use with mammalianhost cells are well known and include, but are not limited to, thoseobtained from the genomes of viruses such as polyoma virus, fowlpoxvirus, adenovirus (such as Adenovirus 2), bovine papilloma virus, aviansarcoma virus, cytomegalovirus, retroviruses, hepatitis-B virus and mostpreferably Simian Virus 40 (SV40). Other suitable mammalian promotersinclude heterologous mammalian promoters, for example, heat-shockpromoters and the actin promoter.

Promoters suitable for use with prokaryotic hosts include thebeta-lactamase and lactose promoter systems; E. coli T7 inducible RNApolymerase; alkaline phosphatase; a tryptophan (trp) promoter system;and hybrid promoters such as the tac promoter. Other known bacterialpromoters are also suitable. Their sequences have been published,thereby enabling one skilled in the art to ligate them to the desiredDNA sequence, using linkers or adapters as needed to supply any usefulrestriction sites.

Additional promoters which may be of interest in controlling expressionof an exendin-4/Tf fusion protein include, but are not limited to: theSV40 early promoter region (Bemoist and Chambon, Nature 290:304-10,1981); the CMV promoter; the promoter contained in the 3′ long terminalrepeat of Rous sarcoma virus (Yamamoto et al, Cell 22:787-97, 1980); theherpes thymidine kinase promoter (Wagner et al., Proc. Natl. Acad. Sci.78:1444-45, 1981); the regulatory sequences of the metallothionine gene(Brinster et al., Nature 296:39-42, 1982); prokaryotic expressionvectors such as the beta-lactamase promoter (Villa-Kamaroff et al.,Proc. Natl. Acad. Sci. U.S.A. 75:3727-31, 1978); or the tac promoter(DeBoer et al., Proc. Natl. Acad. Sci. U.S.A., 80:21-25, 1983).

An enhancer sequence may be inserted into the vector to increase thetranscription in higher eukaryotes of a DNA encoding an exendin-4/Tffusion protein. Enhancers are cis-acting elements of DNA, usually about10-300 bp in length, that act on the promoter to increase transcription.Enhancers are relatively orientation and position independent. They havebeen found 5′ and 3′ to the transcription unit. Several enhancersequences available from mammalian genes are known (e.g., globin,elastase, albumin, alpha-fetoprotein, and insulin). Typically, however,an enhancer from a virus will be used. The SV40 enhancer, thecytomegalovirus early promoter enhancer, the polyoma enhancer, andadenovirus enhancers are exemplary enhancing elements for the activationof eukaryotic promoters. While an enhancer may be spliced into thevector at a position 5′ or 3′ to an exendin-4/Tf fusion protein encodingnucleic acid molecule, it is typically located at a site 5′ to thepromoter.

Expression vectors may be constructed from a starting vector such as acommercially available vector. Such vectors may or may not contain allof the desired flanking sequences. Where one or more of the flankingsequences described herein are not already present in the vector, theymay be individually obtained and ligated into the vector. Methods usedfor obtaining each of the flanking sequences are well known to oneskilled in the art.

Suitable yeast vectors for use in the present invention are described,for example, in U.S. Pat. No. 6,291,212 and include YRp7 (Struhl et al.,Proc. Natl. Acad. Sci. USA 76: 1035-1039, 1978), YEp13 (Broach et al.,Gene 8: 121-133, 1979), pJDB249 and pJDB219 (Beggs, Nature 275:104-108,1978), pPPC0005, pSeCHSA, pScNHSA, pC4 and derivatives thereof. Usefulyeast plasmid vectors also include pRS403-406, pRS413-416 and the Pichiavectors available from Stratagene Cloning Systems (La Jolla, Calif.).Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast integratingplasmids (YIps) and incorporate the yeast selectable markers HIS3, TRP1,LEU2 and URA3. PlasmidspRS413˜41.6 are Yeast Centromere plasmids (YCps).

Such vectors will generally include a selectable marker, which may beone of any number of genes that exhibit a dominant phenotype for which aphenotypic assay exists to enable transformants to be selected.Preferred selectable markers are those that complement host cellauxotrophy, provide antibiotic resistance or enable a cell to utilizespecific carbon sources, and include LEU2 (Broach et al. supra), URA3(Botstein et al., Gene 8: 17, 1979), HIS3 (Struhl et al., supra) or POT1(Kawasaki and Bell, European Pat. No. EP 171,142). Other suitableselectable markers include the CAT gene, which confers chloramphenicolresistance on yeast cells. Preferred promoters for use in yeast includepromoters from yeast glycolytic genes (Hitzeman et al., J. Biol. Chem.225: 12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 1:419-434, 1982; Kawasaki, U.S. Pat. No. 4,599,311) or alcoholdehydrogenase genes (Young at al., in Genetic Engineering ofMicroorganisms for Chemicals, Hollaender et al., p. 355, Plenum, N.Y.,1982; Ammerer, Meth. Enzymol. 101: 192-201, 1983). In this regard,particularly preferred promoters are the TPI1 promoter (Kawasaki, U.S.Pat. No. 4,599,311) and the ADH2-4^(C) (see U.S. Pat. No. 6,291,212promoter (Russell et al., Nature 304: 652-654, 1983). The expressionunits may also include a transcriptional terminator. A preferredtranscriptional terminator is the TPI1 terminator (Alber and Kawasaki,supra). Other preferred vectors and preferred components such aspromoters and terminators of a yeast expression system are disclosed inEuropean Pat. Nos. EP 0258067, EP 0286424, EP0317254, EP 0387319, EP0386222, EP 0424117, EP 0431880, EP 1002095EP, EP 0828759, EP 0764209,EP 0749478, and EP 0889949; PCT Publ. Nos. WO 00/44772 and WO 94/04687;and U.S. Pat. Nos. 5,739,007, 5,637,504, 5,302,697, 5,260,202,5,667,986, 5,728,553, 5,783,423, 5,965,386, 6,150,133, 6,379,924, and5,714,377.

In addition to yeast, fusion proteins of the present invention can beexpressed in filamentous fungi, for example, strains of the fungiAspergillus. Examples of useful promoters include those derived fromAspergillus nidulans glycolytic genes, such as the adh3 promoter(McKnight et al., EMBO J. 4: 2093-2099, 1985) and the tpiA promoter. Anexample of a suitable terminator is the adh3 terminator (McKnight etal., supra). The expression units utilizing such components may becloned into vectors that are capable of insertion into the chromosomalDNA of Aspergillus, for example.

Other vectors are those which are compatible with bacterial, insect, andmammalian host cells. Such vectors include, inter alia, pCRII, pCR3, andpcDNA3.1 (Invitrogen, Carlsbad, Calif.), pBSII (Stratagene), pET15(Novagen, Madison, Wis.), pGEX (Pharmacia Biotech, Piscataway, N.J.),pEGFP-N2 (Clontech, Palo Alto, Calif.), pETL (BlueBacII, Invitrogen),pDSR-alpha (PCT Appl. Publ. No. WO 90/14363) and pFastBacDual(Gibco-BRL, Grand Island, N.Y.).

Additional suitable vectors include, but are not limited to, cosmids,plasmids, or modified viruses, but it will be appreciated that thevector system must be compatible with the selected host cell. Suchvectors include, but are not limited to, plasmids such as Bluescript®plasmid derivatives (a high copy number ColE1-based phagemid,Stratagene), RCA cloning plasmids designed for cloning Taq-amplified PCRproducts (e.g., TOPO® TA Cloning® Kit, PCR2.1® plasmid derivatives,Invitrogen), and mammalian, yeast or virus vectors such as a baculovirusexpression system (pBacPAK plasmid derivatives, Clontech).

Also contained in the expression vectors is a polyadenylation signallocated downstream of the coding sequence of interest. Polyadenylationsignals include the early or late polyadenylation signals from SV40(Kaufman and Sharp, supra), the polyadenylation signal from theadenovirus 5 E1B region and the human growth hormone gene terminator(DeNato at al., Nucl. Acid Res. 9: 3719-3730, 1981). A particularlypreferred polyadenylation signal is the V_(H) gene terminator (see U.S.Pat. No. 6,291,212). The expression vectors may include a noncodingviral leader sequence, such as the adenovirus 2 tripartite leader,located between the promoter and the RNA splice sites. Preferred vectorsmay also include enhancer sequences, such as the SV40 enhancer and themouse (see U.S. Pat. No. 6,291,212) enhancer (Gillies, Cell 33: 717-728,1983). Expression vectors may also include sequences encoding theadenovirus VA RNAs.

After the vector has been constructed and a nucleic acid moleculeencoding an exendin-4/Tf fusion protein has been inserted into theproper site of the vector, the completed vector may be inserted into asuitable host cell for amplification and/or polypeptide expression. Thetransformation of an expression vector for an exendin-4/Tf fusionprotein into a selected host cell may be accomplished by well knownmethods including methods such as transfection, infection,electroporation, microinjection, lipofection, DEAE-dextran method, orother known techniques. The method selected will, in part, be a functionof the type of host cell to be used. These methods and other suitablemethods are well known to the skilled artisan, and are set forth, forexample, in Sambrook at al., Molecular Cloning: A Laboratory Manual, 2ndEd., Cold Spring Harbor Laboratory Press, 1989. Cloned DNA sequencescomprising fusion proteins of the invention may be introduced intocultured mammalian cells by, for example, calcium phosphate-mediatedtransfection (Wigler at al., Cell 14: 725, 1978; Corsaro and Pearson,Somatic Cell Genetics 7: 603, 1981; Graham and Van der Eb, Virology 52:456, 1973.) Other techniques for introducing cloned DNA sequences intomammalian cells, such as electroporation (Neumann at al., EMBO J. 1:841-845, 1982), or lipofection may also be used. In order to identifycells that have integrated the cloned DNA, a selectable marker isgenerally introduced into the cells along with the gene or cDNA ofinterest. Preferred selectable markers for use in cultured mammaliancells include genes that confer resistance to drugs, such as neomycin,hygromycin, and methotrexate. The selectable marker may be anamplifiable selectable marker. A preferred amplifiable selectable markeris the DHFR gene. A particularly preferred amplifiable marker is theDHFR′ (see U.S. Pat. No. 6,291,212) cDNA (Simonsen and Levinson, Proc.Natl. Acad. Sci. USA 80: 2495-2499, 1983). Selectable markers arereviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers,Stoneham, Mass.) and the choice of selectable markers is well within thelevel of ordinary skill in the art.

Host Cells

The present invention also includes a cell, preferably, a yeast cell,transformed to express an exendin-4/Tf fusion protein of the invention.In addition to the transformed host cells themselves, the presentinvention also includes a culture of those cells, preferably amonoclonal (clonally homogeneous) culture, or a culture derived from amonoclonal culture, in a nutrient medium. If the polypeptide issecreted, the medium will contain the polypeptide, with the cells, orwithout the cells if they have been filtered or centrifuged away.

Particularly useful host cells to produce the exendin-4/Tf fusionproteins of the invention are the methylotrophic yeast Pichia pastoris(Steinlein at al., Protein Express. Purif. 6:619-624, 1995). P. pastorishas been developed to be an outstanding host for the production offoreign proteins since its alcohol oxidase promoter was isolated andcloned; its transformation was first reported in 1985. P. pastoris canutilize methanol as a carbon source in the absence of glucose. The P.pastoris expression system can use the methanol-induced alcohol oxidase(AOX1) promoter, which controls the gene that codes for the expressionof alcohol oxidase, the enzyme which catalyzes the first step in themetabolism of methanol. This promoter has been characterized andincorporated into a series of P. pastoris expression vectors. Since theproteins produced in P. pastoris are typically folded correctly andsecreted into the medium, the fermentation of genetically engineered P.pastoris provides an excellent alternative to E. coli expressionsystems. A number of proteins have been produced using this system,including tetanus toxin fragment, Bordatella pertussis pertactin, humanserum albumin and lysozyme.

Strains of the yeast Saccharomyces cerevisiae are another preferredhost. In a preferred embodiment, a yeast cell, or more specifically, aS. cerevisiae host cell that contains a genetic deficiency in a generequired for asparagine-linked glycosylation of glycoproteins is used.S. cerevisiae host cells having such defects may be prepared usingstandard techniques of mutation and selection, although many availableyeast strains have been modified to prevent or reduce glycosylation orhypermannosylation. Ballou et al. (J. Biol. Chem. 255; 5986-5991, 1980)have described the isolation of mannoprotein biosynthesis mutants thatare defective in genes which affect asparagine-linked glycosylation.Gentzsch and Tanner (Glycobiology 7:481-486, 1997) have described afamily of at least six genes (PMT1-6) encoding enzymes responsible forthe first step in O-glycosylation of proteins in yeast. Mutantsdefective in one or more of these genes show reduced O-linkedglycosylation and/or altered specificity of O-glycosylation.

In one embodiment, the host is a S. cerevisiae strain described in PCTPat. Appl. Publ. No. WO 05/061718. For instance, the host can contain apSAC35 based plasmid carrying a copy of the PDI1 gene or any otherchaperone gene in a strain with the host version of PDI1 or otherchaperone knocked out, respectively. Such a construct confers enhancedstability.

To optimize production of the heterologous proteins, it is alsopreferred that the host strain carries a mutation, such as the S.cerevisiae pep4 mutation (Jones, Genetics 85: 23-33, 1977), whichresults in reduced proteolytic activity. Host strains containingmutations in other protease encoding regions are particularly useful toproduce large quantities of the exendin-4/Tf fusion proteins of theinvention.

The host cell, when cultured under appropriate conditions, synthesizesan exendin-4/Tf fusion protein which can subsequently be collected fromthe culture medium (it the host cell secretes it into the medium) ordirectly from the host cell producing it (if it is not secreted). Theselection of an appropriate host cell will depend upon various factors,such as desired expression levels, polypeptide modifications that aredesirable or necessary for activity (such as glycosylation orphosphorylation) and ease of folding into a biologically activemolecule.

Other host cells may be prokaryotic host cells (such as E. coli) oreukaryotic host cells (such as insect or vertebrate cell). A number ofsuitable host cells are known in the art and many are available from theAmerican Type Culture Collection (ATCC), Manassas, Va. Examples include,but are not limited to, mammalian cells, such as Chinese hamster ovarycells (CHO), CHO DHFR(−) cells (Urlaub et al., Proc. Natl. Acad. Sci.U.S.A. 97:4216-20, 1980), human embryonic kidney (HEK) 293 or 293Tcells, or 3T3 cells. The selection of suitable mammalian host cells andmethods for transformation, culture, amplification, screening, productproduction, and purification are known in the art. Other suitablemammalian cell lines are monkey COS-1 and COS-7 cell lines, and the CV-1cell line. Further exemplary mammalian host cells include primate celllines and rodent cell lines, including transformed cell lines. Normaldiploid cells, cell strains derived from in vitro culture of primarytissue, as well as primary explants, are also suitable. Candidate cellsmay be genotypically deficient in the selection gene, or may contain adominantly acting selection gene. Other suitable mammalian cell linesinclude, but are not limited to, mouse neuroblastoma N2A cells, HeLa,mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHKor HaK hamster cell lines. Each of these cell lines is known by andavailable to those skilled in the art of protein expression.

Similarly useful as suitable host cells are bacterial cells. Forexample, the various strains of E. coli (e.g., HB101, DH5α, DH10, andMC1061) are well known as host cells in the field of biotechnology.Various strains of B. subtilis, Pseudomonas spp., other Bacillus spp.,and Streptomyces spp. may also be employed.

Additionally, where desired, insect cell systems may be utilized for theexpression of an exendin-4/Tf fusion protein. Such systems aredescribed, for example, in Kitts et al., Biotechniques 14:810-17, 1993;Lucklow, Curr. Opin. Biotechnol. 4:564-72, 1993; and Lucklow et al., J.Virol., 67:4566-79, 1993. Preferred insect cells are Sf-9 and Hi5(Invitrogen).

Exendin-4/Tf Fusion Protein Production

Host cells containing DNA constructs of the present invention are grownin an appropriate growth medium. As used herein, the term “appropriategrowth medium” means a medium containing nutrients required for thegrowth of cells. Nutrients required for cell growth may include a carbonsource, a nitrogen source, essential amino acids, vitamins, minerals andgrowth factors. The growth medium will generally select for cellscontaining the DNA construct by, for example, drug selection ordeficiency in an essential nutrient which is complemented by theselectable marker on the DNA construct or co-transfected with the DNAconstruct. Yeast cells, for example, are preferably grown in achemically defined medium, comprising a carbon source, e.g. sucrose, anon-amino acid nitrogen source, inorganic salts, vitamins and essentialamino acid supplements. The pH of the medium is preferably maintained ata pH greater than 2 and less than 8, preferably at pH 5.5-6.5. Methodsfor maintaining a stable pH include buffering and constant pH control.Preferred buffering agents include succinic acid and Bis-Tris (SigmaChemical Co., St. Louis, Mo.). Yeast cells having a defect in a generequired for asparagine-linked glycosylation are preferably grown in amedium containing an osmotic stabilizer. A preferred osmotic stabilizeris sorbitol supplemented into the medium at a concentration between 0.1M and 1.5 M, preferably at 0.5 M or 1.0 M.

Suitable media for culturing E. coli cells include, for example, LuriaBroth (LB) and/or Terrific Broth (TB). Suitable media for culturingeukaryotic cells include Roswell Park Memorial Institute medium 1640(RPMI 1640), Minimal Essential Medium (MEM) and/or Dulbecco's ModifiedEagle Medium (DMEM), all of which may be supplemented with serum and/orgrowth factors as necessary for the particular cell line being cultured.A suitable medium for insect cultures is Grace's medium supplementedwith yeastolate, lactalbumin hydrolysate, and/or fetal calf serum, asnecessary.

Typically, an antibiotic or other compound useful for selective growthof transfected or transformed cells is added as a supplement to themedia. The compound to be used will be dictated by the selectable markerelement present on the plasmid with which the host cell was transformed.For example, where the selectable marker element is kanamycinresistance, the compound added to the culture medium will be kanamycin.Other compounds for selective growth include ampicillin, tetracycline,and neomycin.

Baculovirus/insect cell expression systems may also be used to producethe modified Tf fusion proteins of the invention. The BacPAK™Baculovirus Expression System (BD Biosciences (Clontech)) expressesrecombinant proteins at high levels in insect host cells. The targetgene is inserted into a transfer vector, which is cotransfected intoinsect host cells with the linearized BacPAK6 viral DNA. The BacPAK6 DNAis missing an essential portion of the baculovirus genome. When the DNArecombines with the vector, the essential element is restored and thetarget gene is transferred to the baculovirus genome. Followingrecombination, a few viral plaques are picked and purified, and therecombinant phenotype is verified. The newly isolated recombinant viruscan then be amplified and used to infect insect cell cultures to producelarge amounts of the desired protein.

The exendin-4/Tf fusion proteins of the present invention may also beproduced using transgenic plants and animals. For example, sheep andgoats can make the therapeutic protein in their milk. Or tobacco plantscan include the protein in their leaves. Both transgenic plant andanimal production of proteins comprises adding a new gene coding thefusion protein into the genome of the organism. Not only can thetransgenic organism produce a new protein, but it can also pass thisability onto its offspring.

The amount of an exendin-4/Tf fusion protein produced by a host cell canbe evaluated using standard methods known in the art. Such methodsinclude, without limitation, Western blot analysis, SDS-polyacrylamidegel electrophoresis, non-denaturing gel electrophoresis, HighPerformance Liquid Chromatography (HPLC) separation,immunoprecipitation, and/or activity assays such as DNA binding gelshift assays.

If an exendin-4/Tf fusion protein has been designed to be secreted fromthe host cell line, the majority of polypeptide may be found in the cellculture medium. If, however, the polypeptide is not secreted from thehost cells, it will be present in the cytoplasm and/or the nucleus (foreukaryotic host cells) or in the cytosol (for gram-negative bacteriahost cells).

For an exendin-4/Tf fusion protein situated in the host cell cytoplasmand/or nucleus (for eukaryotic host cells) or in the cytosol (forbacterial host cells), the intracellular material (including inclusionbodies for gram-negative bacteria) can be extracted from the host cellusing any standard technique known to the skilled artisan. For example,the host cells can be lysed to release the contents of theperiplasm/cytoplasm by French press, homogenization, and/or sonication,followed by centrifugation.

If an exendin-4/Tf fusion protein has formed inclusion bodies in thecytosol, the inclusion bodies can often bind to the inner and/or outercellular membranes and thus will be found primarily in the pelletmaterial after centrifugation. The pellet material can then be treatedat pH extremes or with a chaotropic agent such as a detergent,guanidine, guanidine derivatives, urea, or urea derivatives in thepresence of a reducing agent such as dithiothreitol at alkaline pH ortris carboxyethyl phosphine at acid pH to release, break apart, andsolubilize the inclusion bodies. The solubilized exendin-4/Tf fusionprotein can then be analyzed using gel electrophoresis,immunoprecipitation, or the like. If it is desired to isolate thepolypeptide, isolation may be accomplished using standard methods suchas those described herein and in Marston et al., Meth. Enz. 182:264-75,1990.

If inclusion bodies are not formed to a significant degree uponexpression of an exendin-4/Tf fusion protein, then the polypeptide willbe found primarily in the supernatant after centrifugation of the cellhomogenate. The polypeptide may be further isolated from the supernatantusing methods such as those described herein.

A number of additional methods for producing polypeptides are known inthe art, and the methods can be used to produce an exendin-4/Tf fusionprotein. See, e.g., Roberts et al., Proc. Natl. Acad. Sci. U.S.A.94:12297-303, 1997, which describes the production of fusion proteinsbetween an mRNA and its encoded peptide. See also, Roberts, Curr. Opin.Chem. Biol. 3:268-73, 1999.

Processes for producing peptides or polypeptides are also described inU.S. Pat. Nos. 5,763,192, 5,814,476, 5,723,323, and 5,817,483. Theprocess involves producing stochastic genes or fragments thereof, andthen introducing these genes into host cells which produce one or moreproteins encoded by the stochastic genes. The host cells are thenscreened to identify those clones producing peptides or polypeptideshaving the desired activity. Other processes for recombinant peptideexpression are disclosed in U.S. Pat. Nos. 6,103,495, 6,210,925,6,627,438, and 6,737,250. The process utilizes E. coli and the E. coligeneral secretory pathway. The peptide is fused to a signal sequence;thus, the peptide is targeted for secretion.

Another method for producing peptides or polypeptides is described inPCT Pat. Appl. Publ. No. WO 99/15650. The published process, termedrandom activation of gene expression for gene discovery, involves theactivation of endogenous gene expression or over expression of a gene byin situ recombination methods. For example, expression of an endogenousgene is activated or increased by integrating a regulatory sequence intothe target cell which is capable of activating expression of the gene bynon-homologous or illegitimate recombination. The target DNA is firstsubjected to radiation, and a genetic promoter inserted. The promotereventually locates a break at the front of a gene, initiatingtranscription of the gene. This results in expression of the desiredpeptide or polypeptide.

Isolation/Purification of Exendin-4/Tf Fusion Proteins

Secreted, biologically active, exendin-4/Tf fusion proteins may beisolated from the medium of host cells grown under conditions that allowthe secretion of the biologically active fusion proteins. The cellmaterial is removed from the culture medium, and the biologically activefusion proteins are isolated using isolation techniques known in theart. Suitable isolation techniques include precipitation andfractionation by a variety of chromatographic methods, including gelfiltration, ion exchange chromatography and affinity chromatography.

A particularly preferred purification method is affinity chromatographyon an iron binding or metal chelating column or an immunoaffinitychromatography using an antigen directed against the transferrin ortherapeutic protein of the polypeptide fusion. The antigen is preferablyimmobilized or attached to a solid support or substrate. In oneembodiment, the substrate is CNBr-activated Sepharose (Pharmacia LKBTechnologies, Inc., Piscataway, N.J.). By this method, the medium iscombined with the antigen/substrate under conditions that will allowbinding to occur. The complex may be washed to remove unbound material,and the exendin-4/Tf fusion protein is released or eluted through theuse of conditions unfavorable to complex formation. Particularly usefulmethods of elution include changes in pH, wherein the immobilizedantigen has a high affinity for the exendin-4/Tf fusion protein at afirst pH and a reduced affinity at a second (higher or lower) pH;changes in concentration of certain chaotropic agents; or through theuse of detergents.

The purification of an exendin-4/Tf fusion protein from solution can beaccomplished using a variety of techniques. If the polypeptide has beensynthesized such that it contains a tag such as Hexahistidine 9 or othersmall peptide such as FLAG (Eastman Kodak Co., New Haven, Conn.) or myc(Invitrogen) at either its carboxyl or amino-terminus, it may bepurified in a one-step process by passing the solution through anaffinity column where the column matrix has a high affinity for the tag.

For example, polyhistidine binds with great affinity and specificity tonickel. Thus, an affinity column of nickel (such as the Qiagen® nickelcolumns) can be used for purification. See, Current Protocols inMolecular Biology, §10.11.8 (supra).

Additionally, an exendin-4/Tf fusion protein may be purified through theuse of a monoclonal antibody that is capable of specifically recognizingand binding to an exendin-4/Tf fusion protein.

When it is preferable to partially or completely purify an exendin-4/Tffusion protein such that it is partially or substantially free ofcontaminants, standard methods known to those skilled in the art may beused. Such methods include, without limitation, separation byelectrophoresis followed by electroelution, various types ofchromatography (affinity, immunoaffinity, molecular sieve, and ionexchange), HPLC, and preparative isoelectric focusing (“Isoprime”machine/technique, Hoefer Scientific, San Francisco, Calif.). In somecases, two or more purification techniques may be combined to achieveincreased purity.

Pharmaceutical Compositions

The exendin-4/Tf fusion proteins of the present invention will generallybe administered in the form of a pharmaceutical composition. Thepharmaceutical composition may, for example, be in a form suitable fororal administration (e.g., a tablet, capsule, pill, powder, solution,suspension), for parenteral injection (e.g., a sterile solution,suspension or emulsion), for intranasal administration (e.g., an aerosoldrops, etc), for rectal administration (e.g., a suppository) or fortransdermal (e.g., a patch). The pharmaceutical composition may be inunit dosage forms suitable for single administration of precise dosages.The pharmaceutical composition will include an exendin-4/Tf fusionprotein of the invention as an active ingredient and can include aconventional pharmaceutical carrier. In addition, it may include otherpharmaceutical agents, adjuvants, etc.

Methods of preparing various pharmaceutical compositions of bioactivepeptides are known in the pharmaceutical sciences art. For example, seeU.S. Pat. Appl. Publ. No. 2005/0009748 (for oral administration); andU.S. Pat. Appl. Publ. Nos. 2004/0157777, 2005/0002927 and 2005/0215475(for transmucosal administration, e.g., intranasal or buccaladministration). See also Remington: The Practice of Pharmacy,Lippincott Williams and Wilkins, Baltimore, Md., 20^(th) ed., 2000.

Traditionally, peptide and protein drugs have been administered byinjection because of the poor bioavailability when administered orally.These drugs are prone to chemical and conformational instability and areoften degraded by the acidic conditions in the stomach, as well as byenzymes in the stomach and gastrointestinal tract. In response to thesedelivery problems, certain technologies for oral delivery have beendeveloped, such as encapsulation in nanoparticles composed of polymerswith a hydrophobic backbone and hydrophilic branches as drug carriers,encapsulation in microparticles, insertion into liposomes in emulsions,and conjugation to other molecules. All of which may be used with thefusion molecules of the present invention.

Examples of nanoparticles include mucoadhesive nanoparticles coated withchitosan and Carbopol (Takeuchi et al., Adv. Drug Deliv. Rev. 47: 39-54,2001) and nanoparticles containing charged combination polyesters,poly(2-sulfobutyl-vinyl alcohol) and poly(D,L-lactic-co-glycolic acid)(Jung et al., Eur. J. Pharm. Biopharm. 50: 147-160, 2000). Nanoparticlescontaining surface polymers with poly-N-isopropylacrylamide regions andcationic poly-vinylamine groups showed improved absorption of salmoncalcitonin when administered orally to rats.

Drug delivery particles composed of alginate and pectin, strengthenedwith polylysine, are relatively acid and base resistant and can be usedas a carrier for drugs. These particles combine the advantages ofbioadhesion, enhanced absorption and sustained release (Liu et al., J.Pharm. Pharmacol. 51: 141-149, 1999).

Additionally, lipoamino acid groups and liposaccharide groups conjugatedto the N- and C-termini of peptides such as synthetic somatostatin,creating an amphipathic surfactant, were shown to produce a compositionthat retained biological activity (Toth et al., J. Med. Chem.42(19):4010-4013, 1999).

Examples of other peptide delivery technologies include carbopol-coatedmucoadhesive emulsions containing the peptide of interest and eithernitroso-N-acetyl-D,L-penicillamine and carbolpol or taurocholate andcarbopol. These were shown to be effective when orally administered torats to reduce serum calcium concentrations (Ogiso et al., Biol. Pharm.Bull, 24: 656-661, 2001). Phosphatidylethanol, derived fromphosphatidylcholine, was used to prepare liposomes containingphosphatidylethanol as a carrier of insulin. These liposomes, whenadministered orally to rats, were shown to be active (Kisel et al., Int.J. Pharm. 216: 105-114, 2001).

Insulin has also been formulated in polyvinyl alcohol)-gel spherescontaining insulin and a protease inhibitor, such as aprotinin orbacitracin. The glucose-lowering properties of these gel spheres havebeen demonstrated in rats, where insulin is released largely in thelower intestine (Kimura et al., Biol. Pharm. Bull. 19: 897-900, 1996.

Oral delivery of insulin has also been studied using nanoparticles madeof poly(alkyl cyanoacrylate) that were dispersed with a surfactant in anoily phase (Damge et al., J. Pharm. Sci. 86: 1403-1409, 1997) and usingcalcium alginate beads coated with chitosan (Onal et al., Artif. CellsBlood Substit. Immobil. Biotechnol. 30: 229-237, 2002).

In other methods, the N- and C-termini of a peptide are linked topolyethylene glycol and then to allyl chains to form conjugates withimproved resistance to enzymatic degradation and improved diffusionthrough the GI wall (www.nobexcorp.com).

BioPORTER® is a cationic lipid mixture, which interacts non-covalentlywith peptides to create a protective coating or layer. The peptide-lipidcomplex can fuse to the plasma membrane of cells, and the peptides areinternalized into the cells.

In a process using liposomes as a starting material, cochleate-shapedparticles have been developed as a pharmaceutical vehicle. A peptide isadded to a suspension of liposomes containing mainly negatively chargedlipids. The addition of calcium causes the collapse and fusion of theliposomes into large sheets composed of lipid bilayers, which thenspontaneously roll up or stack into cochleates (U.S. Pat. No.5,840,707).

Moreover, the present invention includes pulmonary delivery of theexendin-4/Tf fusion protein formulations. Pulmonary delivery isparticularly promising for the delivery of macromolecules which aredifficult to deliver by other routes of administration. Such pulmonarydelivery can be effective both for systemic delivery and for localizeddelivery to treat diseases of the lungs, since drugs delivered to thelung are readily absorbed through the alveolar region directly into theblood circulation.

The present invention provides compositions suitable for forming a drugdispersion for oral inhalation (pulmonary delivery) to treat variousconditions or diseases. The fusion protein formulation could bedelivered by different approaches such as liquid nebulizers,aerosol-based metered dose inhalers (MRI's), and dry powder dispersiondevices. In formulating compositions for pulmonary delivery,pharmaceutically acceptable carriers including surface active agents orsurfactants and bulk carriers are commonly added to provide stability,dispersibility, consistency, and/or bulking characteristics to enhanceuniform pulmonary delivery of the composition to the subject.

Surface active agents or surfactants promote absorption of polypeptidethrough mucosal membrane or lining. Useful surface active agents orsurfactants include fatty acids and salts thereof, bile salts,phospholipid, or an alkyl saccharide. Examples of fatty acids and saltsthereof include sodium, potassium and lysine salts of caprylate (C₈),caprate (C₁₀), laurate (C₁₂) and myristate (C₁₄). Examples of bile saltsinclude cholic acid, chenodeoxycholic acid, glycocholic acid,taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholicacid, deoxycholic acid, glycodeoxycholic acid, taurodeoxycholic acid,lithocholic acid, and ursodeoxycholic acid.

Examples of phospholipids include single-chain phospholipids, such aslysophosphatidylcholine, lysophosphatidylglycerol,lysophosphatidylethanolamine, lysophosphatidylinositol andlysophosphatidylserine, or double-chain phospholipids, such asdiacylphosphatidylcholines, diacylphosphatidylglycerols,diacylphosphatidylethanolamines, diacylphosphatidylinositols anddiacylphosphatidylserines. Examples of alkyl saccharides include alkylglucosides or alkyl maltosides, such as decyl glucoside and dodecylmaltoside.

Pharmaceutical excipients that are useful as carriers includestabilizers such as human serum albumin (HSA), bulking agents such ascarbohydrates, amino acids and polypeptides; pH adjusters or buffers,and salts such as sodium chloride. These carriers may be in acrystalline or amorphous form or may be a mixture of the two.

Examples of carbohydrates for use as bulking agents includemonosaccharides such as galactose, D-mannose, and sorbose,disaccharides, such as lactose and trehalose; cyclodextrins, such as2-hydroxypropyl-.beta.-cyclodextrin, and polysaccharides, such asraffinose, maltodextrins, and extrans, alditols, such as mannitol andxylitol. Examples of polypeptides for use as bulking agents includeaspartame. Amino acids include alanine and glycine, with glycine beingpreferred.

Additives, which are minor components of the composition, may beincluded for conformational stability during spray drying and forimproving dispersibility of the powder. These additives includehydrophobic amino acids such as tryptophan, tyrosine, leucine, andphenylalanine.

Suitable pH adjusters or buffers include organic salts prepared fromorganic acids and bases, such as sodium citrate, and sodium ascorbate;sodium citrate is preferred.

The GLP-1 receptor agonist fusion compositions for pulmonary deliverymay be packaged as unit doses where a therapeutically effective amountof the composition is present in a unit dose receptacle, such as ablister pack or gelatin capsule. The manufacture of blister packs orgelatin capsules is typically carried out by methods that are generallywell known in the packaging art.

U.S. Pat. No. 6,524,557 discloses a pharmaceutical aerosol formulationcomprising (a) a HFA propellant (b) a pharmaceutically activepolypeptide dispersible in the propellant; and (c) a surfactant which isa C₈-C₁₆ fatty acid or salt thereof, a bile salt, a phospholipid, or analkyl saccharide, which surfactant enhances the systemic absorption ofthe polypeptide in the lower respiratory tract. The invention alsoprovides methods of manufacturing such formulations and the use of suchformulations in treating patients.

One approach for the pulmonary delivery of dry powder drugs utilizes ahand-held device with a hand pump for providing a source of pressurizedgas. The pressurized gas is abruptly released through a powderdispersion device, such as a venturi nozzle, and the dispersed powdermade available for patient inhalation.

Dry powder dispersion devices are described in several patents, U.S.Pat. No. 3,921,637 describes a manual pump with needles for piercingthrough a single capsule of powdered medicine. The use of multiplereceptacle disks or strips of medication is described in European Pat.No. EP 0 467 172; PCT Pat. Appl. Publ. Nos. WO 91/02558 and WO 93/09832;and U.S. Pat. Nos. 4,627,432, 4,811,731, 5,035,237, 5,048,514,4,446,862, 5,048,514, and 4,446,862.

The aerosolization of protein therapeutic agents is disclosed inEuropean Pat. No. EP 0 289 336. Therapeutic aerosol formulations aredisclosed in PCT Pat. Appl. Publ. No. WO 90/09781.

Methods of Treatment

The exendin-4/Tf fusion proteins of this invention may be used inconjunction with other pharmaceutical agents for the treatment of thedisease states or conditions described herein. Therefore methods oftreatment that include administering compounds of the present inventionin combination with other pharmaceutical agents are also provided by thepresent invention.

In the methods aspect of the invention, an exendin-4/Tf fusion proteinof the invention, alone or in combination with one or more otherpharmaceutical agents, is peripherally administered to a subjectseparately or together in any of the conventional methods of peripheraladministration known in the art. Accordingly, the exendin-4/Tf fusionprotein or combination may be administered to a subject parenterally(e.g., intravenously, intraperitoneally, intramuscularly orsubcutaneously), intranasally, orally, sublingually, buccally, byinhalation (e.g., by aerosol), rectally (e.g., by suppositories) ortransdermally. Parenteral, but non-oral, administration (e.g.,injection) is a preferred method of administration, and subcutaneousadministration is a preferred method of parenteral administration.Pulmonary delivery by inhalation is also a preferred method ofadministration.

Compositions suitable for parenteral injection generally includepharmaceutically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions, or emulsions, and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers or diluents(including solvents and vehicles) include water, ethanol, polyols(propylene glycol, polyethylene glycol, glycerol, and the like),suitable mixtures thereof, triglycerides including vegetable oils suchas olive oil, and injectable organic esters such as ethyl oleate.

These compositions for parenteral injection may also contain excipientssuch as preserving, wetting, solubilizing, emulsifying, and dispersingagents. Prevention of microorganism contamination of the compositionscan be accomplished with various antibacterial and antifungal agents,for example, parabens, chlorobutanol, phenol, and sorbic acid. It mayalso be desirable to include isotonic agents, for example, sugars andsodium chloride. Prolonged absorption of injectable pharmaceuticalcompositions can be brought about by the use of agents capable ofdelaying absorption, for example, aluminum monostearate and gelatin.

The exendin-4/Tf fusion proteins of the present invention will beadministered to a subject at a dosage that varies depending on a numberof factors, including the mode of administration, the age and weight ofthe subject, the severity of the disease, condition or disorder beingtreated, and the pharmacological activity of the exendin-4/Tf fusionprotein being administered. The determination of dosage ranges andoptimal dosages for a particular patient is well within the ordinaryskill in the art.

For parenteral injection for treatment to reduce blood glucose, theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein as shown inSEQ ID NO: 23 may be administered to a human subject at dosage levels inthe range of about 0.5-50 mg per dose, more preferably, 0.5-20 mg perdose, with dose administration occurring about once per week, once pertwo weeks, or once per month.

For parenteral injection for treatment to reduce body weight, the doserange may be higher than that for reducing blood glucose. Therefore, forparenteral administration for treatment to reduce body weight, theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein as shown inSEQ ID NO: 23 may be administered to a human subject at dosage levels inthe range of about 1-100 mg per dose, with dose administration occurringabout once per week, once per two weeks, or once per month.

The invention also provides an exendin-4/Tf fusion protein of theinvention for use in treating Type II diabetes or reducing blood glucosein a human patient. Further provided is an exendin-4/Tf fusion proteinof the invention for use in treating obesity or decreasing food intakein a human patient. A further aspect of the invention provides the useof an exendin-4/Tf fusion protein of the invention in the manufacture ofa medicament for treating Type II diabetes or reducing blood glucose ina human patient. A yet further aspect provides the use of anexendin-4/Tf fusion protein of the invention in the manufacture of amedicament for treating obesity or decreasing food intake. Features ofthe methods aspect of the invention may apply to each of these aspects.

Embodiments of the present invention are illustrated by the followingExamples. It is to be understood, however, that the embodiments of theinvention are not limited to the specific details of these Examples, asother variations thereof will be known, or apparent in light of theinstant disclosure and appendant claims, to one of ordinary skill in theart. All references cited herein are hereby incorporated by reference intheir entireties.

EXAMPLES Example 1 Construction of Exendin-4/Tf Fusion Proteins

Exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf Fusion Protein

The exendin-4(1-39) DNA sequence (SEQ ID NO: 20) was inserted betweenthe secretion signal sequence (nL) (SEQ ID NO: 19) and mTf sequence (SEQID NO: 22) of pREX0549 using site overlapping extension (SOE) PCR. Twoprimers were designed, P0702 (SEQ ID NO: 28) and P0703 (SEQ ID NO: 29),to insert the sequence using pREX0549 as a template.

The DNA sequence was obtained by back translation of the exendin-4 aminoacid sequence using codons optimal for yeast expression (SEQ ID NO: 30).Initially two PCR products were created using a primer 5′ of the AflIIsite. P0177 (SEQ ID NO: 31) with P0702, or a primer 3′ of the BamHIsite, P0014 (SEQ ID NO: 32) with P0703. The products from thesereactions were gel purified and joined using only the outer primers,P0177 and P0014, in a second round of PCR.

The product from this second reaction was gel purified and digested withthe restriction enzymes AflII and BamHI, as was the plasmid pREX0549.The appropriate products from these reactions were ligated together togive pREX0561, which was DNA sequenced between the AflII and BamHI sitesto confirm correct insertion of the exendin-4 sequence. The expressioncassette was recovered from pREX0561 by restriction enzyme digestionwith NotI and ligated into NotI-digested, calf intestinal alkalinephosphatase-treated pSAC35 to give pREX0589.

Using pREX0561 as a template, SOE PCR was performed with the primersP1810 (SEQ ID NO: 33) and P1811 (SEQ ID NO: 34) to introduce the linkerpeptide sequence (PEAPTD)₂ (SEQ ID NO.: 21) between the encodedC-terminus of the exendin-4 sequence and the N-terminus of the encodedmTf sequence using the same procedure as described above.

The final product from this PCR was gel purified and digested with therestriction enzymes AflII and BamHI, as was the plasmid pREX0549. Theappropriate products from these reactions were ligated together to givepREX0935, which was DNA sequenced between the AflII and BamHI sites toconfirm correct insertion of the sequence encoding (PEAPTD)₂ (SEQ IDNO:5). The expression cassette was recovered from pREX0935 byrestriction enzyme digestion with NotI and ligated into NotI-digested,alkaline phosphatase-treated pSAC35 to give pREX0936. The amino acidsequence for the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein, without the nL leader sequence, is provided herein as SEQ IDNO: 23. The nucleic acid sequence encoding SEQ ID NO: 23 is providedherein as SEQ ID NO: 24. The amino acid sequence for the exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein with the nL leader sequenceis provided herein as SEQ ID NO: 25. The nucleic acid sequence encodingSEQ ID NO: 25 is provided herein as SEQ ID NO: 26.

Additional Exendin-4/Tf Constructs

Exendin-4 has an additional 9 amino acids at the C-terminus as comparedto GLP-1. In the context of the free peptide, these additional residuesare believed to confer increased affinity for the GLP-1 receptor andgreater protease resistance. However, it may also be responsible to somedegree for the immunogenicity of the peptide. Two further constructswere made, using substantially the same procedure as described above, tomake constructs with only the sequence homologous to GLP-1, i.e.,exendin-4(1-31) or exendin-4(1-30), by deletion of the DNA sequencecoding for residues 32-39 or 31-39, respectively. For exendin-4(1-31),primers P0904 (SEQ ID NO: 35) and P0941 (SEQ ID NO: 36) were used andthe appropriate products were ligated (pREX0629/pREX0658). Forexendin-4(1-30), primers P0942 (SEQ ID NO: 37) and P0943 (SEQ ID NO: 38)were used and the appropriate products were ligated (pREX0630/pREX0659).

Constructs were also made with the exendin-4 (1-39) sequence andalternative linkers, e.g., (GGGGS)₃ (SEQ ID NO: 39), PEAPTD (pREX1005)(SEQ ID NO: 6), or an IgG hinge (pREX0938) (SEQ ID NOs: 7-16).

Additional Exendin-4/Tf Constructs with Other Signal Sequences—Impact onRelative Productivity

Constructs were created to express exendin-4/mTf (SEQ ID NO: 23; encodedby SEQ ID NO: 24) linked to the signal sequences HSA/MFα-1 (pREX 1354)(SEQ ID NO: 40; encoded by SEQ ID NO: 41) and modified HSA/MFα-1 (pREX1345) (SEQ ID NO: 42; encoded by SEQ ID NO: 43). A comparison ofproductivity of yeast strains expressing the exendin-4/mTf with thethree different signal sequences revealed a relative productivity ratioas follows for transferrin signal sequence (nL)/HSA/MFα-1/ModifiedHSA/MFα-1: 1/1.75/1.32.

Example 2 Determination of Potency of Exendin-4/Tf Fusion Proteins

Potency was calculated from the measured response of cAMP produced as aresult of GLP-1 receptor-mediated ligand binding in CHO cellstransfected with the rat GLP-1 receptor (CHO-GLP-1R) followingincubation with samples. 96-well tissue culture plates were seeded withCHO-GLP-1R cells and cultured overnight. The following day, the cellswere rinsed with Krebs-Ringer buffer (KRB) and incubated in KRBcontaining the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine(IBMX, 2 mM) to inhibit intracellular enzymes that process cAMP. Serialdilutions of test compounds and controls were prepared in KRB/IBMX andtriplicate wells of cells were inoculated with samples and controls.After incubation, individual sample lysates were then assayed to measurethe increase in intracellular cAMP levels using a competition-basedfluorescent immunoassay (CatchPoint® cAMP Fluorescent Assay Kit,Molecular Devices Corp., Sunnyvale, Calif.). The amount of cAMPaccumulation in cells after GLP-1 receptor-mediated ligand binding isused to determine bioactivity and relative potency.

The data in Table 1 indicate that the exendin-4/Tf fusions are morepotent in activating the GLP-1 receptor than the GLP-1(7-37,A8G,K34A)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein. The mTf moiety in eachfusion protein had the amino acid sequence as shown in SEQ ID NO: 17.

TABLE 1 Potency of GLP-1/mTf and Exendin-4/Tf fusion proteins PlasmidConstruct Potency (nM) pREX0585 GLP-1(7-37; (PEAPTD)₂ mTf 1.3 A8G, K34A)pREX0659 Exendin-4(1-30) (PEAPTD)₂ mTf 0.85 pREX0658 Exendin-4(1-31)(PEAPTD)₂ mTf 0.33 pREX0936 Exendin-4(1-39) (PEAPTD)₂ mTf 0.16

Example 3 MMP-Resistance of the Exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5)mTf Fusion Protein

The exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein (SEQ IDNO: 23) was tested for resistance to inactivation by matrixmetalloprotease I (MMP-1, collagenase) in vitro. Samples ofexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein and theGLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein wereincubated with recombinant MMP-1 for 48 hr at 37° C. and then tested foractivity. When comparing FIG. 1A with FIG. 1B, it can be seen that theexendin-4/Tf fusion protein is resistant to inactivation by MMP-1 (FIG.1B), in contrast to the GLP-1/mTf fusion protein (FIG. 1A). Thisdifference in degradation occurs despite the close similarity in aminoacid sequence in the active portion of the molecules.

Example 4 Effect of the Exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTfFusion Protein on Blood Glucose in Diabetic Mice

Diabetic (db/db) mice were injected with various doses of theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein (SEQ ID NO:23), the GLP-1(7-37,A8G,K34A) (PEAPTD)₂ mTf fusion protein, or exendin-4peptide (Bachem, King of Prussia, Pa.) and blood glucose concentrationswere monitored by analyzing blood samples using a glucometer. As shownin FIG. 2, doses of the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTffusion protein as low as 1.3 nmole/kg significantly reduced the bloodglucose in these animals by 3 hours after subcutaneous injection. Theglucose level almost normalized in all treatment groups and this levelpersisted for 24 hours. The glucose concentrations gradually increasedto the pretreatment levels between 48-72 hours post-treatment, dependingon the dose administered. Exendin-4 peptide did not lower blood glucoseas much as the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein, regardless of the dose, and the exendin-4 glucose loweringeffect had completely dissipated by about 12 hours. This is consistentwith literature reports that the maximum reduction in blood glucoseachievable with exendin-4 is approximately 37%; the reduction seen withthe exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein wasapproximately 70%. The effect of the exendin-4(1-39) (PEAPTD)₂ (SEQ IDNO: 5) mTf fusion protein on blood glucose was also significantlygreater and of a longer duration than equivalent doses of theGLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein.

Example 5 Effect of the Exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTfFusion Protein on Rat Body Weight

Sprague Dawley rats were injected subcutaneously with different doses ofthe exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein (SEQ IDNO: 23), and the exendin-4 peptide. mTf or saline was used as control.The rats were weighed everyday (prior to dosing on dosing days). Animalshad full access to food and water at all times.

As shown in FIG. 3, the animals treated with 10 and 100 nmole/kg dosesof the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein lostweight after the first injection and the weight loss continued for theentire administration period. By day five, the animals treated with 100nmole/kg doses lost an average of 75 grams (17%) body weight compared tocontrols, and the weight loss is related to a drop in food and waterintake. Because of the dramatic and acute weight loss observed, dailyadministration of the drug was stopped at day five. After the 5 dayadministration period, all animals gained weight at a similar rate.However, the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion proteintreated groups, especially the high dose group, still weighed less thanthe control animals at 20 days following the last administration.

Example 6 Predictive Dose for Exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5)mTf Fusion Protein for Glycemic Control in Type II Diabetics and forWeight Loss

Based on published data, a therapeutic single dose of 10 μg of exenatide(BYETTA®) produced a Cmax of 200 pg/mL in humans. The molecular sizedifference between exenatide and the exendin-4(1-39) (PEAPTD)₂ (SEQ IDNO: 5) mTf fusion protein (SEQ ID NO: 23) (4.2 kDa vs. 80.5 kDa)indicates that an exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein blood level of approximately 3.8 ng/mL to be equivalent to thetherapeutic level of exenatide in terms of blood glucose loweringeffect. In addition to the size, the exendin-4(1-39) (PEAPTD)₂ (SEQ IDNO: 5) mTf fusion protein is approximately 5-fold less potent thanexendin-4 based on in vitro testing in CHO cells expressing the humanGLP-1 receptor (FIG. 4). Therefore, to achieve the similar therapeuticactivity of 10 μg of exenatide, a circulating concentration ofapproximately 20 ng/mL of exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTffusion protein would be required.

The exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein and theGLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein aresimilar both in size and structure. The molecular weight for theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein is 80.5 kDaand for the GLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein is 79.6 kDa. The exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTffusion protein is approximately four-eight fold more potent than theGLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein. Meanpharmacokinetic parameters of the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO:5) mTf fusion protein following intravenous and subcutaneousadministration of 1 mg/kg to Cynomolgus monkey are presented in theTable 2. Mean pharmacokinetic parameters of the GLP-1(7-37,A8G,K34A)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein following subcutaneousadministration of 0.6 mg/kg to Cynomolgus monkey are presented in theTable 3.

TABLE 2 Summary of mean pharmacokinetic parameters for the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein after intravenousand subcutaneous administration of 1 mg/kg to male and female Cynomolgusmonkeys Parameter Intravenous Subcutaneous Cmax (ng/mL) 33,981 ± 14,826(4) 5,236 ± 1,038 (4) Tmax (h) 0.542 (4) 9.02 (4) AUC(0-t) (h · ng/mL)567,364 ± 68,102 (4) 278,067 ± 24,367 (4) AUC(inf) (h · ng/mL) 572,314 ±68,660 (4) 280,279 ± 29,261 (3) λ z (h − 1) 0.0313 ± 0.0137 (4) 0.0252 ±0.0084 (3) t½ (h) 25.5 ± 10.3 (4) 29.3 ± 08.2 (3) CL (mL/min/kg) 1.77 ±0.24 (4) — Vz (mL/kg) 65.9 ± 31.0 (4) — F (%) — 49.0

TABLE 3 Summary of mean pharmacokinetic parameters for the GLP-1(7-37,A8G, K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein aftersubcutaneous administration of 0.6 mg/kg to male and female Cynomolgusmonkeys Parameter Males Females Cmax (ng/mL) 2,922 ± 1,530 (3) 3,173 ±1,767 (3) Tmax (h) 12.0 (3) 24.2 (3) AUC(0-t) (h · ng/mL) 168,087 ±58,749 (3) 165,474 ± 32,756 (3) AUC(inf) (h · ng/mL) 171,963 ± 61,998(3) 186,065 ± 140 (2) λ z (h − 1) 0.0216 ± 0.0042 (3) 0.0250 ± 0.0002(2) t½ (h) 32.9 ± 6.78 (3) 27.7 ± 0.23 (2) CL (mL/min/kg) — — Vz (mL/kg)— — F (%) — —

In a separate experiment, the bioavailability of the GLP-1(7-37, A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein was shown to beapproximately 50% in Cynomolgus monkeys.

The elimination half-life (t_(1/2)) of exendin-4(1-39) (PEAPTD)₂ (SEQ IDNO: 5) mTf fusion protein for both intravenous and subcutaneousadministration, range of Tmax, and the bioavailability (F(%)) weresimilar to the GLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein's monkey pharmacokinetic parameters.

Previous human experience with the GLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQID NO: 5) mTf fusion protein indicated that the pharmacokinetics waslinear from doses 30 μg/kg to 900 μg/kg, with mean Tmax at 48 hours, andmean t_(1/2) was about 50 hours. The Cmax was 758±435 ng/mL at a dose of300 μg/kg (or 30 mg/100 kg patient) and 1,609±805 ng/mL at a dose of 900μg/kg (90 mg/100 kg patient). However, the fusion protein did not show arobust effect on blood glucose levels in diabetic subjects at thesedoses, nor at a dose of 1800 μg/kg.

Due to the similarity in size and structure, as well as the similarpreclinical pharmacokinetic profile in monkeys between these twocompounds, the pharmacokinetic characteristics of the exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein in humans are predicted tobe similar to the GLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTffusion protein.

Based upon similarities to GLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5)mTf, a relative four-eight fold higher in vitro potency ofexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein compared toGLP-1(7-37,A8G,K34A) (PEAPTD)₂ (SEQ ID NO: 5) mTf, and the relativefive-fold decrease in in vitro potency for exendin-4(1-39) (PEAPTD)₂(SEQ ID NO: 5) mTf fusion protein as compared to exenatide, it issurprising that an exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein dose of 2 mg can have a glucose lowering effect. Further, a doseof 10 mg per subject, on a weekly dosing basis, would be needed toachieve a steady-state Cmin of 20 ng/mL. Thus, the efficacious dose ofthe exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein (SEQ IDNO: 23) for therapeutic blood glucose lowering ranges from 0.5 to 50 mgper dose administered on a weekly dose basis. Such a dose can also beadministered once per two weeks or once per month.

In addition to its effect on blood glucose, the exendin-4(1-39)(PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein at or above 10 nmole/kg wascorrelated with a reduction in animal body weight in mice and rats.Twenty-four hours after administration of a single dose of 10 or 100nmole/kg of the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein to mice that resulted in an average drop in body weight of 6%and 14%, respectively compared to a mean loss of 1% in the control or 1nmole/kg exendin-4 treated animals. Daily administration ofexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein alsoresulted in 16% weight loss in rats at dose of 100 nmole/kg. Weight losscan be attributed to reduced food intake observed in animals dosed withthe exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein, whichis a known pharmacologic effect of GLP-1 receptor activation. Availabledata indicate that the required dose for weight loss is about 2-3 foldhigher than the doses needed for glucose lowering. Thus, the efficaciousdose of the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein(SEQ ID NO: 23) for weight toss ranges from 1.0 to 100 mg per dose,administered once per week. Such a dose can also be administered onceper two weeks or once per month.

Example 7 Delivery of the Exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTfFusion Protein by Inhalation

Aerosols were generated with an Aerotech II compressed air jet nebulizer(CIS-US Inc., Bedford, Mass.) and directed through a 1.58 cm diameterstainless steel aerosol delivery line into a 24-port flow past rodentexposure system (IN-TOX, ABQ, NM). The exhaust flow rate out of thechamber was ˜11.5 L/min. The nebulizer pressure was maintained at ˜30psi.

To test the effect of aerosolization on the fusion protein, a 10 mg/mLsolution of the exendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusionprotein (SEQ ID NO:23) in 10 mM histidine pH 7.4, 100 mM NaCl wasnebulized and 5 mL of condensed liquid from the aerosol was subsequentlycollected in a biosampler over an eight minute period and tested for itsintegrity and activity. The aerosolization procedure had no detectableadverse effect on the structure of the exendin-4(1-39) (PEAPTD)₂ (SEQ IDNO: 5) mTf fusion protein as judged by SDS-PAGE and SEC-HPLC; there wasno apparent breakdown or aggregate formation. The recovered material wasalso shown to be biologically active.

For the in vivo test, diabetic mice (db/db) were positioned in theinhalation chambers and allowed to breathe an aerosolizedexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein for variouslengths of time. At the end of the inhalation exposure period mice werethen monitored for blood glucose for the next 72 hours. The inhalationtime in the chamber was chosen so that the animals would receive anexposure equivalent to the 0.3, 1 and 3 mg/kg dose administeredsubcutaneously. As a control, these doses were administeredsubcutaneously (SC) to compare in vivo activity to the inhaled route ofadministration. Blood glucose levels in the animals receiving theexendin-4(1-39) (PEAPTD)₂ (SEQ ID NO: 5) mTf fusion protein byinhalation showed a significant drop following exposure to the drug.Evaluation of the circulating levels of the exendin-4(1-39) (PEAPTD)₂(SEQ ID NO: 5) mTf fusion protein indicated a bioavailability ofapproximately 10% for this non-optimized system and formulation.

1. A fusion protein comprising an exendin-4 fused to a modifiedtransferrin (mTf), wherein said fusion protein comprises the amino acidsequence as shown in SEQ ID NO:
 23. 2. A pharmaceutical compositioncomprising the fusion protein of claim 1 and a pharmaceuticallyacceptable carrier.
 3. The pharmaceutical composition of claim 2,wherein the composition is adapted to be administered at a dose rangingfrom 0.5 mg to 50 mg.
 4. The pharmaceutical composition of claim 2,wherein the composition is adapted to be administered at a dose of 1 mgto 100 mg.
 5. The pharmaceutical composition of claim 2, wherein thecomposition is adapted to be administered via inhalation.